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1. Introduction 
1.1. Amiodarone 
1.1.1. Historical Perspective 
Amiodarone (AD) is a bi-iodinated benzofuran derivative (Figure 1.1), that was described as 
an antianginal agent in the early 1960s. AD was later serendipitously found to suppress 
arrhythmias and was used by Argentinian physicians in 1970s to treat resistant arrhythmias. 
In 1985, the United States (US) Food and Drug Administration approved the use of AD for 
treating life-threatening ventricular tachyarrhythmia. The prescription of AD had doubled 
between 1989 and 1994, with a subsequent increase in use. According to Vaughan-Williams 
classification, AD is classified as class III antiarrhythmic agent, as it prolongs myocardial 
repolarisation homogenously via blocking the potassium channel. The drug also possesses 
some characteristics of class I, II and IV antiarrhythmic drugs (Papiris et al., 2010, Vassallo 
et al., 2007). 
 
 
 
Figure 1.1: Chemical structure of AD. (Taylor et al., 2003). 
 
1.1.2. Pharmacokinetics 
Being a cationic (due to its N-diethyl amino side chain) amphiphilic drug, AD exhibits high 
lipophilicity. It hence has a very large volume of distribution (66L/Kg) leading to a delayed 
onset of action (from 2 days to 3 weeks in case of oral therapy) and a longer elimination half-
life spanning from 13 to 142 days for the depletion of the tissue stores upon cessation of the 
chronic therapy, following a 50% reduction in the plasma concentration during the initial 3 to 
10 days (Vassallo et al., 2007, Dharmarajan et al., 2008). AD is primarily metabolized in the 
liver by Cytochrome P450 (CYP) enzymes such as CYP2C8 and CYP3A4 and excreted in 
the faeces (Papiris et al., 2010, Vassallo et al., 2007, Dharmarajan et al., 2008).  The 
excretion via the renal system is minimal (< 1% in urine) (Vassallo et al., 2007). 
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1.1.3. Adverse effects 
Despite its therapeutic potential, AD inflicts several cardiac and extra-cardiac side effects 
(Chang et al., 2007) (Figure 1.2). Hence, standard guidelines recommend the prescription of 
AD by clinicians only in the absence of pre-excitation when other anti-arrhythmic agents are 
either contra-indicated or have failed (January et al., 2014). The lipophilic moiety of the drug 
aids in the accumulation of the drug and its metabolite, N-desethylamiodarone (DEA) in high 
lipid content organs viz adipose tissue, thyroid, liver, lungs and other organs like eyes, skin, 
heart, neuromuscular system, gastrointestinal- and genitourinary- tract (Papiris et al., 2010). 
This results in potentially adverse effects such as hypo- (6%) and hyper- thyroidism (0.9 - 
2%), hepatotoxicity (solely elevated liver enzyme levels, 15 - 30%; hepatitis and cirrhosis, < 
3%), pulmonary toxicity (1 - 17%), microscopic corneal crystalline deposition (> 90%), blue-
gray skin discolouration (4 - 9%), optic neuropathy/neuritis ( 1 - 2%), tremor and ataxia (3 - 
35%), peripheral neuropathy (0.3%) and symptomatic bradycardia (Range et al., 2013, Chang 
et al., 2007, Vassallo et al., 2007). Although AD mediated thyroid and ophthalmic off-target 
effects are more prevalent than AD-induced pulmonary toxicity (AIPT), the latter is often 
fatal (Papiris et al., 2010). AIPT (AD pneumonitis) was first reported in early 1980’s in the 
US and similar cases were also documented in Europe (Chang et al., 2007, Papiris et al., 
2010).  
 
 
Figure 1.2: Potential side effects of AD.  
(https://en.wikipedia.org/wiki/Bradycardia#/media/File:Blausen_0099_bradycardia.png, http://www.fotosearch.co 
m/LIF001/9720b/,http://www.kellogg.umich.edu/theeyeshaveit/sideeffects/images/amiodarone.jpg,http://www.dermaamin.c
om/site/images/clinicalpic/a/amiodarone_hyperpigmentation/amiodarone_hyperpigmentation2.jpg,http://www.gastrohep.co
m/classcases/case29062007_fig_2.jpg,http://transplantationliver.com/wp-content/uploads/201308/Cirrhosis-Hospitals.gif, 
http://photos1.blogger.com/img/250/1358/1024/ Amiodarone%206.jpg). 
Side effects of 
Amiodarone
Skin pigmentation
Cirrhosis
Pulmonary toxicity viz ARDS, 
pulmonary fibrosis
Bradycardia
Hypothyroidism
Hyperthyroidism
Corneal microdeposit
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1.1.4. Pulmonary toxicity of AD is part of the adverse effects 
Two separate drug agency reports rank AIPT as the third and fourth common complications 
(approximately 11%) among all reported adverse effects of AD (Van Cott et al., 2013; 
Ernawati et al., 2008). The incidence of AIPT varies greatly depending on the various risk 
factors involved such as age, dose & duration of AD therapy (cumulative dosage) and pre-
existing pulmonary disease (Papiris et al., 2010). An increased occurrence of AIPT has been 
reported in adult populations. In comparison with patients below 60 years of age, a threefold 
increase in risk of AIPT has been predicted for every 10 years of age in patients above 60 
years of age (Ernawati et al., 2008). Rather than the serum levels, the incidence of AIPT 
could be better correlated with the cumulative dosage of AD. Patient cohorts receiving higher 
dosages of AD ( 400 mg/day) displayed increased frequency of developing severe 
pulmonary toxicity than patient cohorts receiving low doses (≤300 mg/day) (Papiris et al., 
2010, Dharmarajan et al., 2008). Around 6 % of the patients receiving 400 mg/day of AD for 
2 or months develop AIPT, with a mortality rate of 10 - 20% (Chang et al., 2007). Although 
lower doses of AD (200 mg/day) were considered to be safer alternative, reports have shown 
pulmonary complications even at low doses of AD therapy (Ott et al., 2003, Chang et al., 
2007) (Figure 1.3). Patients receiving a cumulative dose of 10g - 150g of AD and/or for a 
time span of 6 -12 months present higher risks of developing AIPT (Papiris et al., 2010).  
 
  
 
Figure 1.3: AIPT in patients receiving low AD dosage of 200mg/day. 
Chest computer tomography (CT) of patients receiving 200 mg/day of AD- (A) -for 9 months, showing multiple 
ground-glass opacities in both lungs. (B) -for 6 months, showing fibrotic changes in both lungs with confluent 
fibrosis and honeycomb appearance evident in the lower part of both lungs. (C) -for one year, displaying 
bilateral pulmonary interstitial fibrosis. (D) -for four years, showing irregular hyperdense mass (amiodaronoma) 
in the right upper lobe of a patient. (Chang et al., 2007, Dharmarajan et al., 2008 and Jarand et al., 2007). 
 
A
BA
C D
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Intravenous administration of AD may significantly increase the lung parenchymal 
concentration of AD even exceeding that of the heart (Papiris et al., 2010). The active 
metabolite of AD, n-desethylAD, also harbour a longer half-life and penetrates tissues 
including lungs approximately five times more than AD (Vassallo et al., 2007, Papiris et al., 
2010). Although pre-existing pulmonary disease was found to be associated with higher risk 
of AIPT, it did not increase the rate of pulmonary death (Olshansky et al., 2005). 
AIPT may clinically manifest in the form of pulmonary fibrosis, chronic interstitial 
pneumonia (CIP), bronchiolitios obliterans organizing pneumonia (BOOP), acute fibrinous 
and organizing pneumonia (AFOP), desquamative interstitial pneumonia (DIP), nodules or 
mass-like lesions (amiodaronoma) (Figure 1.3D), non-specific interstitial pneumonia (NSIP), 
idiopathic pulmonary fibrosis (IPF)-like interstitial pneumonia, diffuse alveolar haemorrhage 
(DAH), acute lung injury (ALI)/ acute respiratory distress syndrome (ARDS) or rarely as 
pleural/pericardial disease (Ott et al., 2003, Papiris et al., 2010).  
 
1.1.5. Mechanisms of AD-induced pulmonary toxicity 
The precise molecular mechanisms underlying AIPT still remain obscure. It is however 
understood that, the interplay between several direct and indirect mechanisms such as 
cytotoxic insult, immune mediated inflammatory process and angiotensin system activation 
might contribute towards AIPT (Range et al., 2013, Jarand et al., 2007) (Figure 1.4). 
 
 
 
Figure 1.4: Possible mechanisms involved in AIPT.  
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AD-induced direct cytotoxicity involves accumulation of phospholipids, inhibition of 
mitochondrial function, generation of toxic oxygen radicals, disturbance of calcium 
homeostasis, inhibition of ionic pumps, alterations in physical properties of the cell 
membrane and influence on the activity of G proteins (Baritussio et al., 2001, Range et al., 
2013). The direct exposure to AD induces apoptosis in various mammalian lung cell types 
including human alveolar epithelial cells (AECs) in vitro (Bargout et al., 2000). 
As a cationic amphiphilic compound, AD accumulates in the acidic milieu of the lysosomes 
to levels higher than the extracellular concentration and inhibits lysosomal phospholipases viz 
phospholipase A1 and A2 (Baritussio et al., 2001), thereby blocking phospholipid catabolism. 
This results in the accumulation of phospholipid-bound AD within the lysosomes of cells 
such as macrophages, type II pneumocytes, endothelial cells, interstitial and other intra-
alveolar inflammatory cells of the lung and cells within other organs, thus leading to 
phospholipidosis. The drug induced phospholipidosis takes the form of a “foamy cell 
response”, where whorled ultrastructural lamellar inclusion bodies are found in the foamy 
lipid-laden macrophages (Jarand et al., 2007, Papiris et al., 2010) (Figure 1.5).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
 
 
 
Figure 1.5: Foamy macrophages in AIPT. 
(A) Hematoxylin-eosin (HE) staining of percutaneous fine-needle aspirate of the right upper lung lobe of a 
patient treated with AD (200 mg/day) for four years displaying numerous myofibroblasts and aggregates of 
foamy macrophages (black arrow) and chronic interstitial inflammation (white arrow). (B) Transmission 
electron micrograph of the same patient showing multiple lamellar bodies within macrophages. (Jarand et al., 
2007). 
 
Such laminated inclusions are also witnessed in other hereditary lysosomal storage diseases 
viz the Niemann-Pick disease, Fabry disease and other amphiphilic drug induced 
phospholipidosis (Chung et al., 2005). When such foamy cells occupy the intra-alveolar or 
the interstitial region, they may effectively reduce the surface for gas exchange. This type of 
storage lung disorder is referred as “lipoid pneumonia” (Papiris et al., 2010, Bedrossian et al., 
1997). 
A B
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AD is also a potential mitochondrial toxicant, well known to cause mitochondrial dysfunction 
and generate reactive oxygen species (ROS) (Nicolescu et al., 2008; Bolt et al., 2001). The 
negative membrane potential of the inner mitochondrial membrane drives the accumulation 
of this cationic drug into the mitochondria. AD gets protonated in the acidic intermembrane 
space and accrues electrophoretically into the mitochondrial matrix, where it releases the 
acquired proton due to the alkaline milieu. This leads to an initial uncoupling effect. Further, 
the concentrated drug in the matrix inhibits -oxidation of fatty acids and also hinders 
complex I and complex II of the respiratory chain, thereby decreasing ATP formation 
(Fromenty et al., 1990a,b, Felsar et al., 2013). This respiratory chain inhibition results in 
enhanced ROS formation, which eventually induces lipid peroxidation. These events might 
further hamper the respiratory chain, thereby inflicting even more oxidative damage, 
ultimately resulting in rapid loss of mitochondrial membrane potential (m), release of 
cytochrome c (Cyt C) and cell death (Begriche et al., 2006; Marceau et al., 2012).  
Immunological mechanisms such as an imbalance between T helper (Th) type I and type II 
lymphocyte subpopulations and production of cytokines viz tumour necrosis factor- and 
transforming growth factor- (TGF-) have also been implicated in contributing to AIPT.  
(Chung et al., 2001, Papiris et al., 2010, Van Cott et al., 2013).  The third mechanism 
proposed to be involved in AIPT is the angiotensin II, which is chronically induced during 
congestive heart failure. Angiotensin II has been demonstrated to enhance AD mediated 
apoptosis of human lung AECs (Nikaido et al., 2010) and promote fibrosis in a rat bleomycin 
model by stimulating angiotensin II type I receptor and TGF- (Otszka et al., 2004). AD-
induced apoptosis of AECs was significantly abrogated by angiotensin converting enzyme 
inhibitor (Captopril) and angiotensin receptor blocker (Losartan) in vitro (Bargout et al., 
2000, Uhal et al., 1998). AD-induced pulmonary fibrosis in rats was also averted by co-
administration of angiotensin system antagonists Captopril or Losartan, which was evident by 
reduced incidence of alveolar epithelial cells type II (AECII) apoptosis and decreased 
collagen deposition in the alveolar walls (Uhal et al., 2003). 
 
1.1.6. Murine model of AD-induced pulmonary fibrosis 
Since a murine model for AD-induced pulmonary fibrosis had not been described earlier 
(except a study elaborating the protective effects of the neferine in AD treated mice), a 
systemic analysis of surfactant alterations, lysosomal and endoplasmic reticulum (ER) stress 
had been performed and published recently by our research group (Mahavadi et al., 2014). 
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Intratracheal administration of AD (0.8mg/kg) in C57 black 6 (C57BL/6) mice on every fifth 
day resulted in the development of full blown fibrosis in the lungs with marked septal 
thickening, patchy interstitial fibrosis, lymphoplasmacellular infiltration, extracellular matrix 
deposition (marked by increased collagen) and increased AECII size from day 7 onwards in 
comparison to the vehicle (Veh) treated C57BL/6 mice (Figure 1.6 A - C). Decreased lung 
compliance and increased lung hydroxyproline levels have also been reported in this model 
(Figure 1.6 D and E). Transmission electron micrographs of day 7 of AD treated mice 
revealed fragmented alveolar lining, denuded basal lamina and interstitial edema (Mahavadi 
et al., 2014) (Figure 1.6 F). 
Bronchoalveolar lavage fluids (BALF) obtained from AD treated mice displayed a prominent 
increase in the total phospholipids (PL), with modest changes in the PL profile in the 
lipidomics analysis of the alveolar surfactant pool (Mahavadi et al., 2014).  
 
 
 
 
 
 
 
D. E.
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Figure 1.6: AD-induced pulmonary fibrosis in C57Bl/6 mice. (A, B, C) H&E and trichrome staining showing 
the development of fibrosis and increased collagen deposition in the complete left lung of C57Bl/6 mice from 
day 7 until day 28 of AD treatment. (D) Graphical representation of decreased lung compliance and (E) 
increased hydroxyproline content in the total right lung of day 7, 14, 21 and 28 of AD treated mice.  (F) 
Transmission electron micrographs showing fragmented alveolar lining, denuded basal lamina and interstitial 
edema in day 7 of AD treated mice lung tissue and thickened septal walls (asterisk) and AECII with abundant 
and enlarged lamellar bodies (block arrows) in day 14 of AD treated mice lung tissue. Alv: alveolar space, alv 
epi: alveolar epithelium, ed: edema, bl: basal lamina, col: collagen, endo: endothelium, cap: capillary. 
(Mahavadi et al., 2014). 
 
Same analysis also revealed distinct changes in the fatty acid profiles, where a significant 
reduction in dipalmitoylphosphotidylcholine (DPPC), saturated phosphotidylcholine (PC) and 
saturated phosphotidylglycerol (PG) had been observed with their respective unsaturated 
counterparts (unsaturated phosphotidylcholine and unsaturated phosphotidylglycerol) 
reportedly increased in the BALF of AD treated mice (Mahavadi et al., 2014). 
Phosphotiylethanolamine based plasmalogens (PE P) were also increased in the AD treated 
BALF samples. Mature forms of surfactant proteins (SP), SP-B and SP-C remained 
unchanged between the BALF of AD- versus Veh- treated mice (Mahavadi et al., 2014).  
Not just the BALF of AD treated mice; the lungs of the AD treated mice as well displayed an 
increased amount of PL. In addition, significantly increased levels of surfactant proteins 
(prosurfactant (pro) proteins: proSP-B and proSP-C and mature surfactant protein forms: 
mature SP-B and mature SP-C) were witnessed in AD treated mice lungs versus the Veh and 
an increase in proSP-C were also noted in AD treated mouse lung epithelial (MLE)12 cells 
(MLE12) for various time points (8-, 16- and 24- hours of AD treatment)  (Figure 1.7 C). 
Corroborating this, an increased number and size of lamellar bodies were observed in 
hyperplastic AECII found around the areas of interstitial fibrosis in day 14 of AD treated 
mice lung with abundant intra-alveolar surfactant. In addition, lipidomics analysis from the 
lungs of AD treated mice revealed a significant increase in bis (monoacylglycero) phosphate 
(BMP)/ lysobisphosphatidic acid (LBPA), the biomarker for AD-induced phospholipidosis 
that is present within the internal vesicles of multivesicular bodies (MVBs) alongside with 
F.
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cholesterol esters and other PLs were also elevated in the lipidomics analysis of AD treated 
mice lungs (Mahavadi et al., 2014).  
Three different theories have been proposed regarding the mechanism by which chronically 
injured AECII could drive lung fibrosis (Günther et al., 2012). The first theory believes in the 
epithelial-mesenchymal transition (EMT), where the injured epithelial cells are suggested to 
transdifferentiate into active fibroblasts, which proliferates and results in fibrosis. The second 
theory claims a loss of control over the mesenchymal cells by the dying AECII and releasing 
a number of pro-fibrotic factors viz TGF- and factor X, facilitating the fibroblast 
proliferation and collagen synthesis leading to pulmonary fibrosis. The third suggested 
mechanism is the chronically injured AECII releasing factors such as stromal cell-derived 
factor-1 by, which would attract the circulating fibrocytes into lung and aid in the expansion 
of the local fibroblast population, thus developing fibrosis (Günther et al., 2012). 
Under AD treatment, significantly increased apoptosis of AECII had been documented 
accompanied with elevated lysosomal and ER stress. Prominently increased amounts of 
apoptosis protein: cleaved caspase 3, lysosomal protein: cathepsin D and ER stress marker 
proteins: activating transcription factor (ATF) - 6 and C/EBP homologous protein (CHOP) 
were found in the lung homogenates of AD treated mice against the Veh treated control mice 
(Figure 1.7 A and B) and in 8-, 16- and 24- hours of AD treated MLE12 cells (Figure 1.7 C). 
Immunohistochemical analysis of day 7 of AD- and day 28 of Veh- treated mice serial lung 
sections for cleaved caspase 3, cathepsin D, ATF6 and proSP-C demonstrated localization of 
increased cleaved caspase 3, cathepsin D and ATF6 to the AECII of day 7 of AD-treated 
mice versus the day 28 of Veh treated controls (Mahavadi et al., 2014) (Figure 1.7 D - F). 
 
 
  
C.
A.
B.
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Figure 1.7: Elevated apoptosis, lysosomal and ER stress under AD treatment. (A, B) Western blot images 
showing increased expression of cleaved caspase 3, cathepsin D, ATF6 and CHOP in the lung homogenates of 
day 7, 14, 21 and 28 of AD treated mice. (C) Western blot images depicting elevated expression of cleaved 
caspase 3, proSP-C, cathepsin D, ATF6 and CHOP in 8-, 16- and 24- hours of AD treated MLE12 cell lysates 
D.
E. F.
D.
E. F.
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(D - F) Immunohistochemical analysis of serial lung sections of AD (day 7) treated mice displaying increased 
expression of cleaved caspase 3, cathepsin D and ATF6 in AECII (proSP-C). (Mahavadi et al., 2014). 
 
1.2. Autophagy 
1.2.1. Introduction 
In order to maintain cellular homeostasis, an exquisite balance is demanded between 
anabolism (biosynthesis) and catabolism (degradation) of macromolecules. In eukaryotic 
cells, there are two main systems involved in degradation namely the ubiquitin proteasomal 
system (UPS) and the autophagy-lysosomal system (Puissant et al., 2012). UPS involves 
polyubiquitination of short-lived target proteins via a series of enzymatic reactions that are 
eventually delivered to the 26S proteasomes for degradation. Protein targets with a minimum 
of four ubiquitin chains interconnected through lysine48 (K48) are are delivered into the 
proteasome. Large protein complexes and protein aggregates are poor substrates of the UPS 
system (Korolchuk et al., 2010, Puissant et al., 2012). In contrast, the latter highly conserved 
catabolic process known as autophagy (Greek for “self eating”) encompasses sequestering 
and degradation of long-lived and bulkier substrates such as macromolecules like proteins 
(misfolded, oligomers or aggregates), lipids or nucleic acids or damaged organelles via 
lysosomes. Substrates with lysine63 (K63)-linked ubiquitin chains or monoubiquitination are 
usually targeted to the autophagy-lysosomal system (Korolchuk et al., 2010). Autophagy has 
been implicated in several different processes viz development, differentiation, innate and 
adaptive immunity, ageing and cell death. It ensures to replenish the cell with nutrient supply 
during starvation and acts as a quality control mechanism to protect the cell from toxic 
macromolecules, damaged organelles or invading pathogens. Accumulating evidence 
demonstrates a pathomechanistic role of autophagy in several human diseases (Johansen and 
Lamark, 2010, Wirawan et al., 2012). 
 
1.2.2. Types of autophagy 
Autophagy has been categorized into three types namely i) Chaperone mediated autophagy 
(CMA) ii) Microautophagy and iii) Macroautophagy (Wirawan et al., 2012) (Figure 1.8).  
CMA is a selective form of autophagy that involves sequestering of proteins with degenerate 
pentapeptide sequence motif ‘KFERQ’ that binds to a complex of heat shock cognate 70 
(Hsc70) and its co-chaperones, which later associates with lysosomal receptor, lysosomal-
associated membrane protein-2A (LAMP2A) and transports the substrate protein into the 
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lumen of lysosome for degradation (Johansen and Lamark, 2010, Wirawan et al., 2012). 
Microautophagy refers to the direct invagination of the lysosomal membrane to engulf parts 
of cytoplasm, which are subsequently degraded once they are completely enclosed (Wirawan 
et al., 2012). 
 
Figure 1.8: Types of autophagy (Wirawan et al., 2012). 
 
Macroautophagy is the most well studied form of autophagy that generally involves non-
selective bulk degradation marked by expansion of a crescent shaped double membranous 
structure called the phaghophore (isolation membrane) into a double-membrane vesicle called 
the autophagosome, encompassing the cytoplasmic contents to be degraded, eventually fusing 
with the lysosome to form autolysosome to degrade its contents (Johansen and Lamark, 2010) 
(Figure 1.9). A total of around 30 AuTophaGy-related genes (Atg) proteins have been 
identified so far in yeast, many of these have known orthologs (ATG) in higher eukaryotes 
(Feng et al., 2014) (Figure 1.10). Amidst this, 15 “core” ATG proteins are commonly 
required for different autophagy pathways (Johansen and Lamark, 2010, Feng et al., 2014). 
 
 
 
Figure 1.9: General steps in macroautophagy  
(http://www.wormbook.org/chapters/www_autophagy/autophagyfig1leg.jpg). 
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Figure 1.10:  Orthologous core Atg/ATG protein machineries in yeast and mammals. (Feng et al., 2014). 
 
1.2.3. Regulation of macroautophagy 
In mammals, macroautophagy is a multistep process that includes i) initiation, ii) nucleation 
iii) elongation and iv) maturation/ degradation (Puissant et al., 2012, Wirawan et al., 2012) 
(Figure 1.9). Diverse input signals such as nutrients, growth factors, hormones, intracellular 
Ca
2+
 concentration, adenosine triphosphate (ATP) levels, hypoxia, accumulation of misfolded 
proteins and many other factors determine the induction of macroautophagy (Wirawan et al., 
2012). It is a tightly regulated process and many of these signals target membrane target of 
rapamycin complex 1 (mTORC1) that encompasses mTOR, regulatory associated protein of 
Introduction
 
14 
 
mTOR (raptor), proline rich AKT substrate 40 kDa (PRAS40) and G-protein--subunit-like 
protein (GL) (Puissant et al., 2012, Wirawan et al., 2012).  
When mTORC1 is active (as during the nutrient replete state), it inhibits autophagy by 
phosphorylating uncoordinated-51 (unc-51) - like kinase 1 or 2 (ULK1/2, a homologue of 
yeast Atg1) and ATG13 (a homologue of yeast Atg13) of the ULK1/2 complex, which is 
known to activate autophagy initiation (Wirawan et al., 2012, Feng et al., 2014). ULK1 
kinase can be activated both by AMP-activated protein kinase (AMPK) dependent (glucose 
starvation) and independent (amino acid starvation) pathways (Feng et al., 2014). But when 
phosphorylated, there is a disruption of interaction between ULK1 and AMPK, thus 
inhibiting autophagy initiation. The ULK1/2 complex also harbors focal adhesion kinase 
family interacting protein of 200kDa (FIP200, a putative Atg17 homologue) and ATG101 
protein. ATG13 acts as connecting bridge between ULK1/2 and FIP200 (Johansen and 
Lamark, 2010, Feng et al., 2014) (Figure 1.10, 1.11). 
When mTORC1 is inactive (during nutrient deprivation or in the presence of rapamycin), the 
mTORC1 complex dissociates from the ULK1/2 complex, promoting ULK1/2 activity and 
hyperphosphorylation of ATG13, FIP200 (Wirawan et al., 2012, Feng et al., 2014).The 
activated ULK1 complex also phosphorylates activating molecule in beclin-1 regulated 
autophagy (AMBRA1) and BECN1 of another autophagy-inducing complex, the 
phosphotidylinositiol-3-kinase class 3 (PIK3C3) complex (Wirawan et al., 2012, Feng et al., 
2014). PIK3C3 complex is comprised of PIK3C3, AMBRA, Beclin-1, p150 and UV-
radiation resistance associated gene (UVRAG) or ATG14L (Wirawan et al., 2012). During 
nutrient rich conditions, PIK3C3 complex is connected to the cytoskeleton via AMBRA. But 
phosphorylation of AMBRA1 by ULK1 releases the phosphotidylinositiol-3-kinase class 3 
(PIK3C3) complex  from the microtubules-associated dynein motor complex and facilitates 
its relocation to the endoplasmic reticulum, which is considered to be a major organelle 
involved in the formation of autophagosome (Wirawan et al., 2012). Beclin-1 (Atg6) within 
the PIK3C3 complex provides a platform for binding of other interactors that regulate the 
kinase activity of PIK3C3 (Wirawan et al., 2012). This results in generation of phosphotidyl-
inositol-3-phosphate (PI3P), which further recruits other ATG proteins viz WD repeat protein 
interacting with phosphoinositides 1 and 2 (WIPI1 and WIPI2), mATG2 and double-FYVE 
containing protein-1 (DFCP-1) to the site of autophagosome formation, facilitating a process 
referred as autophagosome nucleation (Wirawan et al., 2012) (Figure 1.10, 1.11).  
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ULK1 also plays a vital role in trafficking the multispanning membrane protein, mATG9 to 
the site of autophagosome formation during starvation. mATG9 might be supplying lipids for 
autophagosomes elongation (Wirawan et al., 2012) (Figure 1.10, 1.11).  
 
 
 
Figure 1.11: Molecular outlook of macroautophagy. (http://www.cellsignal.com). 
 
Two ubiquitin (Ub)-like protein conjugating systems involving two Ub-like modifiers 
LC3/Atg8 and ATG12 (part of the evolutionarily conserved autophagic machinery) play a 
pivotal role in the elongation, shaping and sealing of the autophagosome (Wirawan et al., 
2012). ATG7 acts as the E1-like enzyme for both the conjugating systems. ATG7 activates 
ATG12, which subsequently gets conjugated it to ATG5 by the action of E2-like enzyme, 
ATG10. The ATG12-ATG5 complex further interacts with ATG16L1 to form a trimer, which 
homodimerizes and transiently associates with the growing outer membrane of the 
autophagosome and has been suggested to determine its curvature (Johansen and Lamark, 
2010, Wirawan et al., 2012).  
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Figure 1.12: Generation of lipidated LC3 (LC3-II) from pro-LC3. (Klionsky et al., 2012). 
 
ATG16L1 complex also acts as an E3-ligase for the second conjugation reaction involving 
lipidation of MAP1LC3 (microtubule-associated protein 1 light chain-3), a homologue of 
ATG8.  MAP1LC3 is produced as a soluble ‘pro’ form, where a pentapeptide sequence at the 
carboxy-terminus is cleaved by the cysteine protease, ATG4B, to generate a soluble 
MAP1LC3-I form. Through the concerted action of the second ubiquitin-like protein 
conjugation system (involving ATG7 (E1-like enzyme), ATG3 (E2-like enzyme) and 
ATG16L1 (E3-ligase) ‘soluble’ MAP1LC3-I gets converted to ‘membrane bound’ 
MAP1LC3-II by the addition of phosphotidylethanolamine (PE) (Wirawan et al., 2012, Feng 
et al., 2014) (Figure 1.11 and 1.12). MAP1LC3-II particularly localizes to the 
autophagosomal membrane, hence MAP1LC3-II serves as an autophagy specific marker, 
particularly an autophagosomal marker per se. Upon completion of the vesicle formation, 
ATG4 cleaves the MAP1LC3-II bound to the outer membrane of the autophagosome by a 
process of deconjugation. The MAP1LC3-II associated with the inner membrane of the 
autophagosomes remains intact until it fuses with the lysosomes, where it gets degraded 
(Johansen and Lamark, 2010, Wirawan et al., 2012, Klionsky et al., 2012). In mammals, 
there are atleast seven ATG8 homologues identified so far that has been classified into two 
subfamilies - i) three MAP1LC3 proteins (MAP1LC3A, B and C) and four gamma 
aminobutyrate receptor associated protein (GABARAP) and GABARAP-like proteins 
(GABARAPL1, L2 and L3). Although all except GABARAPL3 are demonstrated to be 
involved in autophagosome synthesis, the LC3B remains to be the most commonly examined 
ATG8 homologue in the mammalian system (Johansen and Lamark, 2010, Klionsky et al., 
2012).  
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Upon completion of the autophagosome formation, it either fuses with early or late 
endosomes to form amphisome, which then fuses with the lysosome or directly fuses with the 
lysosome. The outer membrane of the autophagosome fuses with the lysosomes, thereby 
releasing the inner autophagosomal membrane and its content into the lysosomal lumen 
(autophagic body) (Wirawan et al., 2012). Lysosomes are acidic membrane bound organelles 
enriched with hydrolytic enzymes, which are responsible for degradation of macromolecules 
delivered to them via autophagy, endocytosis or phagocytosis (Eskelinen, 2006). Lysosomal 
membrane has a crucial role in protecting other cellular constituents from the degradative 
potential of lysosomal hydrolases, whereas lysosomal membrane proteins are involved in 
maintaining an acidified lysosomal lumen, transport of free aminoacids, fatty acids, 
carbohydrates and other nutrients derived from lysosomal digestion into the cytosol 
(Eskelinen, 2006, Wirawan et al., 2012). About 50% of the proteins in the lysosomal 
membrane are estimated to be Lysosome Associated Membrane protein 1 (LAMP1) and 
LAMP2. These proteins share about 37% amino acid sequence homology and share common 
functions in vivo (Eskelinen, 2006). Mice deficient in both LAMP1 and LAMP2 have been 
demonstrated to have an embryonic lethal phenotype, whereas mice deficient for either 
LAMP1 or LAMP2 were reported to be viable and fertile, with LAMP2 single deficiency 
exhibiting more serious consequences. Increased accumulation of autophagic vacuoles had 
been described in both LAMP2 single knockout and LAMP1/LAMP2 double knockout mice 
(Eskelinen, 2006). In addition, LAMP1/LAMP2 double knockout mice embryonic fibroblasts 
were reported to demonstrate altered lysosomal appearance, perturbed cholesterol metabolism 
and unaffected protein degradation rate (Eskelinen, 2006). 
 
1.2.4. Selective autophagy 
In contrast to macroautophagy, which is primarily considered a non-selective bulk 
degradation process of long lived proteins and organelles, more selective forms of autophagy 
are increasingly becoming apparent (Johansen and Lamark, 2010, Wirawan et al., 2012). 
Aggrephagy is the process of selective autophagic degradation of protein aggregates or 
misfolded proteins and the mechanism of autophagy responsible for the selective targeting 
and degradation of organelles viz mitochondria, peroxisomes, endoplasmic reticulum, 
ribosomes and nuclei are referred as mitophagy, pexophagy, reticulophagy, ribophagy and 
nucleophagy respectively (Johansen and Lamark, 2010, Puissant et al., 2012, Wirawan et al., 
2012).  
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1.3. Mitophagy 
1.3.1. Mitochondrial Quality control 
There are three major pathways of mitochondrial quality control. First, mitochondria have 
two AAA protease complexes on their inner mitochondrial membrane with their catalytic 
sites exposed on both sides of the membrane to degrade unfolded or misfolded membrane 
proteins. This process is further assisted by the cytosolic proteasomes, which also participate 
in degrading unfolded and misfolded mitochondrial membrane proteins. The second pathway 
involves budding of vesicles from mitochondrial tubules. These buds are sequestered with 
selected mitochondrial cargos (e.g. oxidised mitochondrial proteins) that are eventually 
targeted to the lysosomes for degradation. While these two pathways are specific for the 
degradation of a subset of mitochondrial proteins, the third pathway known as ‘mitophagy’ 
involves sequestering of the entire damaged or superfluous mitochondria within double-
membranous vesicular structures called autophagosomes, which then fuse with the lysosomes  
for degradation (Ashrafi and Schwarz, 2013) (Figure 1.13).  
 
 
 
Figure 1.13: Pathways involved in mitochondrial quality control. (Ashrafi and Schwarz, 2013).  
 
In addition to the above stated pathways, it is also imperative for mitochondria to maintain a 
steady state level of superoxide and hydrogen peroxide production. Under physiological 
conditions, these molecules act as cell signalling moieties but when the mitochondrial 
respiratory chain incurs damage, they often turn deleterious by causing serious oxidative 
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damage to the proteins, lipids and DNA (Bolisetty et al., 2013). Their toxicity is severely 
enhanced when superoxide and hydrogen peroxide reacts with heme or heme proteins 
resulting in generation of pro-ferryl forms of heme. Thus, the biosynthesis and degradation of 
heme is under tight regulation. Heme synthesis is regulated via δ-aminolevulinic acid 
synthase activity and the enzymatic detoxification of heme is carried out by heme oxygenase 
(HO) isoenzymes (Bolisetty et al., 2013). Heme oxygenases catalyze the conversion of heme 
into biliverdin IXα, carbon monoxide and Fe2+ (Donnelly and Barnes, 2001) (Figure 1.14). 
There are three different forms of heme oxygenases namely HO-1, HO-2 and HO-3. HO-1 is 
a major inducible isoform, whereas HO-2 and HO-3 are constitutively expressed isoforms 
(Lee et al., 2002).  
 
 
Figure 1.14: HO-1 enzyme activity. 
 
HO-1 is upregulated in response to a variety of stimuli viz free heme, oxidative stress, 
inflammation, heavy metals and UV radiation (Bindu et al., 2011). Apart from being an 
antioxidative protein, HO-1 also serves as an anti-inflammatory and anti-apoptotic protein 
(Otterbein, et al., 2003). Increased expression of HO-1 has been reported in neurons resisting 
oxidative stress induced cell death, cardiovascular diseases, inflammatory diseases, lung 
injury and other pathological conditions (Bindu et al., 2011). Although mitochondrion is the 
site for heme synthesis and harbours heme-containing proteins in the electron transport chain, 
it does not contain HO-1 (Bolisetty et al., 2013). Studies have demonstrated cytoprotective 
nature of oxidative stress driven translocation of HO-1 to mitochondria and the probable 
involvement of carbon monoxide in mitochondrial biogenesis, suggesting an intimate link 
between HO-1 and mitochondrial function (Bolisetty et al., 2013, Slebos et al., 2007).  HO-1 
has also been shown to regulate autophagy in varied pathological conditions. Interestingly, 
HO-1 has been implicated to prevent or  induce autophagy, under different pathological 
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conditions. (Yun et al., 2014, Lin et al., 2014, Li et al., 2013, Bolisetty et al., 2010, Kim et 
al., 2008b). 
 
1.3.2. Mitochondrial fission - a prerequisite for mitophagy  
Mitophagy is a catabolic process, in which the core machinery of macroautophagy is 
harnessed for selective clearance of superfluous mitochondria. Mitochondria are dynamic 
organelles that undergo continuous fusion and fission within the cell (Ding and Yin, 2012). 
Each mitochondrion has to be separated from the mitochondrial network to be readily 
engulfed by the autophagosomes (Ashrafi and Schwarz, 2013) (Figure 1.15 A). In situ, 
mitochondria appear as short round-shaped or elongated organelles with a major axis of  5 
µm, whereas autophagosomes are globular organelles with a diameter of  1 µm. In order to 
avoid sterical hindrance, mitochondrial fission is imperative for the occurrence of mitophagy. 
Hence, mitochondrial fission always precedes mitophagy (Gomes and Scorrano, 2013). It has 
also been shown that the fusion event often leads to fission of two subsets of daughter 
mitochondria with increased or decreased mitochondrial membrane potentials, where the 
daughter mitochondria with higher membrane potential proceeds to fusion and the 
depolarized mitochondria are removed by mitophagy. The dynamin-like GTPase, dynamin-
related protein (Drp1) and mitochondrial fission 1 (Fis1) protein actively participate in the 
process of mitochondrial fission (Ashrafi and Schwarz, 2013, Ding and Yin, 2012, Gomes 
and Scorrano, 2013) (Figure 1.15 B).   
 
 
 
Figure 1.15: Mitochondrial fission and mitophagy. (A) Fragmentation of mitochondria (fission) from the 
mitochondrial network for ensuing mitophagy. (B) Molecular players viz DRP1 and Fis1 involved in 
mitochondrial fission.  
(Ashrafi and Schwarz, 2013 and http://ajpendo.physiology.org/content/ajpendo/303/1/E31/F1.large.jpg). 
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1.3.3. Mitophagy - Pathways 
The fragmented and damaged mitochondria are targeted to the autophagosomes via several 
pathways such as Bcl-2/E1B-19kDa interacting protein 3 (Bnip3), Bnip3-like (Bnip3L) or the 
PTEN-induced putative kinase 1 (Pink1) - Parkin pathway (Figure 1.16). 
 
 
 
Figure 1.16: Mitophagy pathways. (Adapted from Tait and Green, 2012). 
 
Mitophagy via the mitochondrial autophagic receptors: Bnip3 and Bnip3L/NIX are the Bcl-2 
homology 3 (BH3) domain containing homologous proteins with 53 - 56 % of aminoacid 
sequence identity. These proteins get inserted into the outer membrane of the mitochondria 
through its C-terminal transmembrane domains, while their N-termini remain exposed to the 
cytosol.  The N-terminus of Bnip3 harbours WXXL-like motif, which is important for its 
direct binding to Atg8 family of proteins viz LC3, GABARAP. A similar motif has also been 
reported in Bnip3L (Ding and Yin, 2012, Hanna et al., 2012) (Figure 1.16 and 1.17).  
 
 
 
Figure 1.17: Mitophagy via Bnip3/Bnip3L. (Kubli and Gustafsson, 2012). 
 
The expression of Bnip3 and Bnip3L are not ubiquitous but are induced under certain 
conditions. Under hypoxia, the expression of Bnip3 has been demonstrated to be upregulated 
in a hypoxia-inducible factor-1 (HIF-1) dependent manner, thereby driving mitophagy as an 
adaptive metabolic response to prevent ROS generation. Bnip3L has been shown to be highly 
expressed during erythroid differenetiation, where it plays a pivotal role in eliminating 
mitochondria from mature reticulocytes (Ding and Yin, 2012).  
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Mitophagy via Pink1 - Parkin pathway: Pink1 is a mitochondrial serine/threonine kinase, 
which is usually quite low in healthy cells due to its rapid cleavage and degradation by 
Presenilins-associated rhomboid-like protein (PARL) present in the inner mitochondrial 
membrane. When m dissipates, Pink1 gets stabilized on the outer mitochondrial 
membrane, where it forms a complex with the translocase of the outer membrane and recruits 
the E3 ubiquitin ligase, Parkin from the cytosol. Following its mitochondrial translocation, 
Parkin ubiquitinates a subset of outer mitochondrial membrane proteins, which are then 
recognized by the ubiquitin binding autophagic adaptor proteins like sequestosome-
1(SQSTM1)/p62  or neighbor of BRCA1 gene 1 (NBR1) (Ding and Yin, 2012; Johansen and 
Lamark, 2011). Ubiquitination is the process of tagging a substrate with a single 
evolutionarily conserved 76 aminoacids protein called ubiquitin or with poly ubiquitins. 
(Shaid et al., 2013). Thus these cargo adaptor molecules binding ubiquitinated mitochondria, 
also bind Atg8 family proteins viz LC3 or GABARAP through its LC3- interacting region 
(LIR) by which they facilitate the delivery of the damaged mitochondria to the 
autophagosomes (Ding and Yin, 2012; Johansen and Lamark, 2011) (Figure 1.18 A and B). 
Recent report by Fu et al., 2013 also shows Glycoprotein 78 (Gp78) E3 ubiquitin ligase to 
mediate mitophagy in a Parkin independent manner. 
 
 
 
 
Figure 1.18: Mitophagy via Pink1-parkin & p62 pathway. (A) Recruitment of Parkin upon stabilization of 
Pink1 on the outer mitochondrial membrane, leading to the ubiquitination of outer membrane proteins and 
targeting to the autophagosomes. (B) p62 mediated targeting of the ubiquitinated mitochondria to the 
autophagosomes via binding to LC3. (Kubli and Gustafsson, 2012). 
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Domain structure of p62 and NBR1: The human p62 protein is 440 aminoacids long with N-
terminal protein-protein interacting Phox and Bem1 (PB1) domain followed by ZZ- type zinc 
finger domain, LC3-interacting region (LIR), Keap1 interacting region (KIR) and a C-
terminal Ub-associated domain (UBA). p62 homopolymerizes via the PB1 domain and also 
interacts with other proteins including NBR1 through this domain. NBR1 protein with 966 
aminoacids has a similar domain organization like that of p62 in addition to few other 
domains like the coiled coil (CC) domain required for dimerization and an evolutionary 
conserved four tryptophan (FW) domain (Johansen and Lamark, 2011) (Figure 1.19).  Both 
proteins have a UBA domain through which they bind ubiquitinated substrates. Depending on 
which of the seven lysine (K) residues ubiquitin monomer is linked, the chains are called K6, 
K11, K27, K29, K33, K48 or K63 ubiquitin chains. Lysine 48 (K48) linked ubiquitin chains 
are canonical signals for targeting substrates for proteasomal degradation, whereas lysine 63 
(K63) linked ubiquitin chains (hereafter referred as ubiquitin.K63) target substrates for 
degradation via autophagy (Shaid et al., 2013).  
 
 
 
Figure 1.19: Domain structure of p62 and NBR1. (Johansen and Lamark, 2011). 
 
p62 exhibits a very strong binding affinity towards ubiquitin.K63, whereas NBR1 binds both 
lysine 48 (K48)- and K63-linked diUb. Through their LIR, these proteins bind to the 
autophagosomes thereby targeting the ubiquitinated substrates to the autophagosomes 
(Johansen and Lamark, 2011). 
 
1.4 Macroautophagy in murine model of AD-induced pulmonary fibrosis 
AD gets accumulated in the acidic milieu of the lysosomes to levels higher than the 
extracellular concentration (Baritussio et al., 2001, Stadler et al., 2008) due to the low 
retrograde diffusion of the protonated (AD
+
) molecule.  This cationic drug uptake is usually 
mediated by Vacuolar (V)-ATPase, which also results in ensuing vacuolization. The presence 
of autophagic signal is considered to be a generalized response to the cationic drugs that 
induce vacuolization (Marceau et al., 2012). AD induces large vacuoles in the cytoplasm of 
human macrophages (Stadler et al., 2008, Morissette et al., 2009) and evolves towards 
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D.
E.
persistent macroautophagy (Morissette et al., 2009). Further, AD also causes the increased 
accumulation of multilamellar bodies (Somani et al., 1987).  
Corroborating this, recent publications from our laboratory demonstrate increased number 
and size of lamellar bodies in AECII (Mahavadi et al., 2014) and AD-induced vacuolization 
in MLE12 cells, that have been positively labeled for LC3B following AD treatment. In line 
with this, AD increases the conversion of LC3BI to LC3BII in MLE12 cells, AECII and in 
mice (Figure 1.20 A, B and C). Immunohistochemical analysis of day 7 of AD- and day 28 of 
Veh- treated mice serial lung sections for LC3B and proSP-C also revealed localization of 
increased LC3B to the AECII of day 7 of AD-treated mice against the day 28 of Veh treated 
controls (Figure 1.20 D). Further, immunogold labelling analysis of the lung tissue of AD and 
Veh treated mice for LC3B revealed an intense labelling of LC3B on the limiting membrane 
and interior of the lamellar bodies of AECII under AD treatment (Figure 1.20 E). In addition, 
a connection between the lamellar bodies and autophagosomes via membranes present within 
the AECII of AD treated mice has also been demonstrated using electron tomography. 
Supporting this, an efficient fusion of autophagosomes with lysosomes were evident in AD 
treated MLE12 cells (Figure 1.20 F) (Mahavadi et al., 2015). 
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Figure 1.20: AD-induced macroautophagy in MLE12 cells. (A, B, C) Western blot analysis displaying 
increased LC3B expression in 8-, 16- and 24- hours of AD treated MLE12 cells, 24 hours of AD treated AECII 
and in day 7, 14, 21 and 28 of AD treated mice lung homogenates respectively. (D) Immunohistochemical 
analysis of serial lung sections of AD (day 7) treated mice showing increased expression of LC3B in AECII 
(proSP-C) (E) Immunogold labeling analysis images demonstrating intense LC3B binding to the limiting 
membrane and interior of the lamellar bodies (LB) in the AECII of AD (day 7) treated mice lung sections. (F) 
Immunofluorescence analysis of 8 hours of AD treated MLE12 cells showing co-localization (indicated by 
arrows of LC3B (red) with LAMP2 (green). Nuclei are stained with DAPI (blue). (Mahavadi et al., 2015). 
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2. Aim of the study 
It is well known that AD, a potential anti-arrhythmic drug, causes severe pulmonary toxicity 
(including pulmonary fibrosis) in patients receiving even low doses. Apoptosis of AECII has 
been suggested to be a prime factor driving the development of the pulmonary fibrosis. 
Recent work from our laboratory revealed altered surfactant homeostasis, increased 
accumulation of lamellar bodies and elevated lysosomal stress in AECII alongside with 
AECII apoptosis in the murine model of AD-induced pulmonary fibrosis. Further, AD also 
induced the formation of LC3 positive vacuoles and increased LC3B lipidation (autophagy 
marker) in AECII, thus raising the possibility of an involvement of macroautophagy in AD-
induced pulmonary fibrosis. Dysfunctional mitochondria and enhanced oxidative stress have 
also been reported in AD-induced pulmonary toxicity. Hence, in the present study, we aimed 
to investigate the following: 
 
 To decipher the role of macroautophagy in AD-induced AECII apoptosis: is it a pro- or 
an anti-survival mechanism? 
 To determine autophagy flux under AD treatment. 
 To investigate if AD promotes mitochondrial autophagy (mitophagy) in the murine model 
of AD-induced pulmonary fibrosis. 
 To find out the possible pathway(s) by which the damaged mitochondria are targeted to 
the autophagic machinery for degradation in AD treated AECII.  
 To discern the probable role of mitophagy and oxidative stress in AECII upon AD 
treatment.  
 To assess the antioxidative response and its role in AD treated AECII.
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3. Materials and Methods 
3.1. Materials 
3.1.1. Equipment 
Name Company 
Cell Culture Hood HERAsafe Hereaus, Germany  
Cell Culture Incubator, Hera Cell, 150i Thermo Scientific, Germany 
Centrifuge, Universal 30RF Hettich, Germany  
Centrifuge, Mikro 200R Hettich, Germany  
Dounce homogenizer B.Braun, Germany 
Dry block thermostat Ditabis, Germany  
Dynal MPC-L (Magnetic Particle concentrator)  Dynal, Norway 
EMXmicro ESR Spectrometer Bruker, Germany 
Fluoroscence microscopy Leica, Germany 
Freezer +4°C  Bosch, Germany 
Freezer -20 °C  Bosch, Germany 
Freezer -80°C  Bosch, Germany 
Gel imager INTAS, Germany 
Light microscope Leica, Germany 
Magnetic Stirrer Heidolph, Germany  
NanoZoomer Digital Pathology (NDP) version 
2.5.85 Hamamatsu Photonics, Germany 
Precellys homogenizer Peqlab, Germany 
Spin down VWR, Germany 
Trans-Blot SD Semi-Dry Transfer Cell Bio-Rad, Germany 
Vortex machine  VWR, Germany 
Water Bath Julabo, Germany  
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Others 
Cell culture plate - 6 well Greiner Bio-one, Austria 
Cell Scraper Sarstedt, Germany 
Cell strainer 70 µM, 40 µM and 10 µM Nylon BD falcons 
Chamber slide - 8 Well BD falcon, Germany 
Falcon - 15 ml Greiner Bio-one, Austria 
Falcon - 50 ml Corning, USA 
Filter 0.22 µm - syringe-driven Sarstedt, Germany 
Filter tips: 10 µl, 100 µl and 1000 µl Eppendorf, Germany 
Gel blotting paper GE Healthcare, UK 
Glass bottles: 250, 500, 1000 ml  Roth, Germany 
Glass Slides, Automat Star Langenbrinck, Germany  
Glass slides, SuperFrost Plus Langenbrinck, Germany  
Immobilon - PVDF transfer membrane Millipore, Germany 
Mini-PROTEAN® Tetra Handcast Systems 
(SDS-Electrophoresis chamber) 
Bio-Rad, Germany 
Pipette Eppendorf, Germany 
Pipette boy Eppendorf, Germany 
Pipette tips Biozym, Germany  
Steritop filter unit 150 ml, 45 mm Millipore, USA 
Syringe 20G BD microlance, Germany 
Syringes Braun, Germany  
Tissue Culture Dish, 100 x 20 mm Sarstedt, Germany 
Whatmann gel blotting paper GE Healthcare, Germany 
Softwares 
Image J 1.49a software National Institute of Health, USA 
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Leica Application Suite Advanced Fluorescence 
(LAS AF) software, version 4.3 Leica, Germany 
NDP.view2 software Hamamatsu Photonics, Germany 
 
3.1.2. Reagents  
Name Company 
2-Mercaptoethanol Sigma-Aldrich, Germany 
Acrylamide solution, Rotiphorese gel 30 Carl Roth, Germany 
Amiodarone Sigma-Aldrich, Germany 
Ammonium Chloride Sigma-Aldrich, Germany 
Ammonium persulphate  Sigma-Aldrich, Germany 
Ammonium sulphate Merck, Germany 
AP-fast red kit Zytomed, Germany 
Bafilomycin A1 Invivogen, USA 
BEGM singlequots Lonza, Germany 
Beta-mercaptoethanol Sigma-Aldrich, Germany 
Bicinchoninic acid (BCA) protein assay Life technologies, Germany 
Bovine serum albumin (BSA) Sigma-Aldrich, Germany 
Bromophenol blue Merck, Germany 
Bronchial Epithelial Cell Growth Medium 
(BEGM) Lonza, Germany 
CathepsinD siRNA (mouse) 
Santa Cruz, Biotechnology, 
Germany 
Chloroquine Sigma-Aldrich, Germany 
CMH Noxygen, Germany 
DAB-kit Zytomed, Germany 
dharmaFECT Thermoscientific, Germany 
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Dispase Corning, USA 
DMEM-F12 Life technologies, Germany 
DMSO Carl Roth, Germany 
DNAse  Fermentas, Germany 
Dulbecco's PBS GE Healthcare, Austria 
Dyna beads M-280 Tosyl activated Life technologies, Germany 
Dynabeads Biotin Binder Life technologies, Germany 
EDTA SERVA, Germany 
Ethanol absolut Fluka, Germany 
Fetal calf serum (FCS)  Roth, Germany 
Foetal Bovine Serum Sigma-Aldrich, Germany 
Glycerol Sigma-Aldrich, Germany 
Glycine Carl Roth, Germany 
HCL 32% Carl Roth, Germany 
Heme oxygenase 1 siRNA (mouse) 
Santa Cruz, Biotechnology, 
Germany 
HEPES Carl Roth, Germany 
Hydrobeta estradiol (ß-estradiol) Sigma Aldrich, Germany 
Hydroxycortisone Lonza Walkersville, USA 
Immobilon western Chemiluminescent HRP 
substrate Millipore, Germany 
Isoflurane Baxter, Germany 
ITS (100X) PAN biotech, Germany 
Keratinocyte growth factor Peprotech, Germany 
LC3B siRNA (mouse) 
Santa Cruz, Biotechnology, 
Germany 
L-Glutamine  Gibco, Germany 
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Matrigel  Basement membrane matrix BD biosciences, USA 
Mdivi-1 Sigma-Aldrich, Germany 
Methanol Carl Roth, Germany 
Na2EDTA Sigma-Aldrich, Germany 
N-acetyl-L-Cysteine (NAC) Sigma-Aldrich, Germany 
Non-targetting siRNA GE Healthcare, Germany 
Pageruler protein ladder Thermoscientific, Germany 
Paraformaldehyde Carl Roth, Germany 
Pen-strep Life technologies, Germany 
Phenylmethylsulfonyl fluoride (PMSF) Sigma-Aldrich, Germany 
Potassium bicarbonate Sigma-Aldrich, Germany 
pSOD Sigma-Aldrich, Germany 
Rotiphorese Carl Roth, Germany 
Saccharose/ Sucrose Carl Roth, Germany 
Skim Milk powder Sigma-Aldrich, Germany  
SnPP Frontier scientific, USA 
Sodium azide Merck, Germany 
Sodium Chloride Sigma-Aldrich, Germany 
Sodium deoxycholate Merck, Germany 
Sodium dodecyl sulphate Merck, Germany 
TEMED Sigma-Aldrich, Germany 
Tris Carl Roth, Germany 
Triton-X100 Sigma-Aldrich, Germany 
Trypsin PAA, Austria 
Turbofect Thermoscientific, Germany 
VECTASHIELD mounting medium with DAPI Vector laboratories, USA 
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3.1.2.1. Preparation of solutions 
AD and Veh stock solution 
About 5 mg (0.005 g) of AD was weighed and dissolved in 5 ml of filtered cell culture grade 
distilled water in a sterile falcon. The falcon was then warmed at 65
o
C for 10 minutes in an 
incubator until AD was completely dissolved.  The volume was made upto 50 ml with sterile 
complete DMEM/F12 medium. Similar procedure was followed for preparing Veh solution.  
 
Autophagy inhibitors 
Bafilomycin A1 was prepared by dissolving in filter sterilized dimethylsulfoxide (DMSO) 
and a working concentration of 100 nM was used for experiments. Chloroquine was 
dissolved in cell culture grade aqua dest and a working concentration of 10 or 30 µg/ml was 
used.  
 
Others 
Mdivi-1 and tin protoporphyrin (SnPP) were dissolved in filter sterilized DMSO and a 
working concentrations of 20 µM and 25 µM was used respectively. N-acetyl-L-Cysteine 
(NAC) was dissolved in filtered cell culture grade distilled water and a working concentration 
of 2mM was used.  
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3.2. Methods 
3.2.1. Mammalian cell culture 
3.2.1.1. Culturing of MLE12 cells  
MLE12 cells obtained from ATCC, Manassas, USA were grown in 10 cm
2
 tissue culture 
plates in Dulbecco’s modified eagle medium, (DMEM)/F12 (supplemented with the 
following components) at 37°C in 95% air, 5% CO2. 
 
 
 
 
 
 
 
 
 
 
 
 
After the cells reach 80-90 % confluency, the cells were passaged. For passaging, cells were 
washed twice with 1X PBS and incubated with 3 ml of trypsin at 37°C for 2-3 minutes, after 
which the cells were dispensed from tissue culture plate and suspended into 10 ml of 
complete DMEM/F12 medium to nullify the activity of trypsin. The cell suspension was 
centrifuged at 5000xg for 5 minutes. The supernatant was removed and cells were diluted in 
complete DMEM/F12 medium and plated (1:10) to a new culture dish.  
 
3.2.1.2. Small interfering RNA (siRNA) transfection 
For siRNA transfection, 2.5 x10
5 
MLE12 cells were plated in each well of a 6 well plate and 
incubated overnight at 37°C and 5% CO2. Once the cells reached 70 - 80% confluency the 
next day, the transfection procedure was followed according to the manufacturer’s protocol 
for 48 hours with cathepsin D siRNA (CatDsi) or LC3B siRNA or Heme oxygenase-1 (HO-
1) siRNA obtained from Santa Cruz Biotechnology, Germany or with siRNA for non-
targeting sequence from Fischer scientific, Germany using dharmaFect. In brief, 20 µM stock 
Components Concentration/Volume 
Hydrocortisone (100 µM) 10 nM 
Hydrobetaestradiol (100 µM) 10 nM 
ITS -  5% 
Insulin  0.005 mg/ml 
Transferrin 0.01 mg/ml 
Selenite 30 nM 
HEPES 10 mM 
L-Glutamine 5 ml 
Foetal Calf Serum (FCS) 2% 
Penstrep 1% 
Materials and Methods
 
34 
 
siRNA solution was prepared by resuspending siRNA in 165 µl of RNAse free water, from 
which 2 µM working siRNA solution was freshly made for each transfection. Then the 
siRNA and dharmaFect were separately suspended in serum and antibody free medium and 
incubated at room temperature (RT) for 5 minutes. After which, they both were gently mixed 
and incubated together for 20 minutes. This was resuspended in serum containing medium, 
which were added dropwise to MLE12 cells and incubated for 48 hours. The following day, 
solutions were removed from MLE12 cells and replaced with complete DMEM/F12 medium 
and treated with AD (10 µg/ml) or Veh for 8 hours.  
 
3.2.1.3. Recombinant plasmid transfection 
3x10
4 
MLE12 cells/well were plated in an eight well chamber slide and incubated for 24 
hours at 37°C and 5% CO2 for adherence. 0.5 µg of endotoxin free recombinant plasmid, 
green fluorescent protein (GFP) tagged LC3B was dispensed in 50 µl of serum free MLE12 
cell culture medium, to which 2 µl of TurboFect was added and mixed gently and incubated 
at RT for 20 minutes. Meanwhile, the cells were washed twice with 1X PBS and replaced 
with fresh complete MLE12 culture medium. To this, the incubated mixture was added drop 
wise and incubated overnight at 37°C and 5% CO2. The following day, AD (10 µg/ml) and 
Veh treatment was carried out for 8 hours, after which immunofluorescence protocol was 
performed as described in 3.3.4. 
 
3.2.1.4. Isolation of murine AECII 
AECII were isolated from the lungs of C57BL/6 mice (with prior authorization obtained for 
animal work from Regierungspräsidium Giessen, GI 20/10-Nr.A53/2012). Intraperitoneal 
injection of a mixture of rompon, ketamine and heparin (in the ratio 2:2:1) was used to 
anesthetize the mice. To exsanguinate the animal, the abdominal cavity was opened and the 
renal artery was severed. Following this, the lungs were perfused with 10 ml of saline to clear 
off the blood and then filled with dispase until the small lobe is inflated. 0.5 ml of 1% low-
melting agarose in DMEM medium was then injected into lung through the trachea and left 
for 5 minutes to let the agarose solidify. The lungs were then isolated and incubated in 5 ml 
of warm dispase for 45 minutes at 37°C. Following incubation, lungs were finely chopped in 
7 - 8 ml of medium II under the hood and incubated at RT for 10 minutes with gentle 
shaking. A homogenized cell suspension was subsequently prepared from this incubated lung 
samples by gently flushing it through a 10 ml pipette. The resulting suspension was filtered 
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through 70 µm, 40 µm and 10 µm nitex filters and the filtrate was then centrifuged at 950 
rpm at 4°C for 10 minutes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The pellet obtained was resuspended in 5 ml of lysis buffer and incubated at RT for 8 minutes 
on a shaker. The suspension was again filtered through 70 µm nitex filter and equal volume 
of 1X PBS was added and re-centrifuged at 950 rpm at 4°C for 10 minutes. The resulting 
pellet was then suspended in 1 ml of medium III. The cell number was then counted using 
haemocytometer and the total number of cells in the suspension was calculated using the 
following formula -  
 
 
 
1 ml of medium III was then added for every 10 million cells. Following this, 0.9 µl of CD 
45, 0.675 µl of CD16/32 and 0.4 µl of CD 31 antibodies / million cells were added and 
Medium I 
Components Concentration/Volume 
DMEM 500 ml 
HEPES 1.25 M 
1% Penstrep 1% 
Medium II 
Components Concentration/Volume 
Medium I 50 ml 
DNAse 0.04mg/ml 
Medium III 
Components Concentration/Volume 
Medium I 50 ml 
FCS 10% 
Erythrocyte (ER) - lysis buffer (pH 7.4) 
Components Concentration/Volume 
dH20 1000 ml 
NH4Cl 8,29g 
KHCO3 
Na2EDTA 
1g 
0.037 g 
Total number of cells = Average number of cells in four quadrants x 4 x 2.5 
x total volume of cell suspension (in µl). 
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incubated at 37°C for 30 minutes in a water bath with intermittent shaking. Meanwhile, the 
biotinylated beads were prepared in 15 ml falcon tubes according to the following  
 calculation- 
 
 
The ‘C’ volume of beads was taken and washed thrice with 1ml of 1X PBS using a magnetic 
seperator and resuspended in volume ‘C’ of 1X PBS. Following incubation, equal volume of 
medium I was added to the cell suspension and centrifuged at 950 rpm at 4°C for 10 minutes. 
The resulting pellet was suspended in medium I in volume equal to ‘B’. The suspension was 
then added to the beads with no more than 10 ml per 15 ml falcon and left on the shaker for 
20 minutes at RT. Falcons were then left undisturbed on a magnetic seperator for 15 minutes. 
The cell suspension was carefully collected and centrifuged at 950 rpm at 4°C for 10 minutes. 
Cell pellet was resuspended in Medium I and purity of the cells was analyzed for proSP-C 
staining.  
 
3.2.1.5. Culturing of murine AECII 
For culturing murine AECII on a 6 well plate, each well of the plate was coated with 500 µl 
of Matrigel, a basement membrane matrix. After coating all the wells, the plate was incubated 
at 37°C for 1 hour without CO2. The matrigel was then equilibrated with sterile AECII 
culture medium with the following components - 
 
 
  
A = (X million cells x 0.45) + (X million cells x 0.2) 
B = A/3 (ml medium), C = B x 50 (µl beads) 
Components Concentration/Volume 
BEGM 500 ml 
FBS 5% 
BPE 2ml 
Insulin  5 mg/ml 
Gentamycin 5ml 
Retinoic acid 0.1 µg/ml 
Transferrin 10 mg/ml 
Triiodothyronine 0. 5 ml 
Epinephrine 0.5 mg/ml 
hEGF 0.5 µg/ml 
KGF (Freshly added) 1 µl/ml 
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The coated plate with the sterile AECII culture medium was incubated at 37°C for 45 minutes 
to 1 hour with CO2. Each coated well was seeded with half million to 1 million cells and 
allowed to adhere overnight at 37°C and 5% CO2. The following day, adhered AECII were 
treated with AD (10 µg/ml) or Veh for 24 hours. To harvest the AECII from the matrigel, 
about 1 ml of dispase was added and left at 37°C for 15 - 20 minutes. The dissolved matrigel 
along with the cells were collected in a falcon and washed twice or thrice with 1X PBS and 
centrifuged at 5000 rpm at 4°C for 5 minutes and the resultant pellet was shock frozen in 
liquid nitrogen and  stored at -80°C until the cell lysates were prepared.  
 
3.2.1.6. Preparation of cell lysates and protein quantification 
The AD or Veh treated MLE12 cells and AECII were lysed using the lysis buffer, to which 
phenylmethylsulfonyl fluoride (PMSF) was added in the ratio of 100:1.  
 
 
 
 
 
 
 
 
 
 
 
 
The lysates were shock frozen using liquid nitrogen and incubated on ice for 15 to 20 minutes 
and this step was repeated for three times with the final incubation on ice for 1 hours. The 
lysates were then centrifuged at 12,000 rpm for 10 minutes at 4°C. The supernatants were 
collected and protein concentrations were analyzed using bicinchoninic acid (BCA) - protein 
assay kit (Life technologies, Germany) according to the manufacturer’s instructions using 
standard decreasing concentrations of bovine serum albumin (BSA). Samples for western 
blotting were then prepared from these supernatants and the remaining samples were stored at 
-80°C until further use. 
 
3.2.2. Sample preparation for western blot 
The samples for the western blot analysis were prepared by reducing the protein samples 
obtained from tissues or cells using 10% -mercaptoethanol containing 4X loading buffer and 
Lysis buffer 
Components Concentration/Volume 
Tris 50 mM 
NaCl 50 mM 
EDTA 5 mM 
Triton X-100 1% 
Sodium deoxycholate 0.5% 
Materials and Methods
 
38 
 
boiling it for 10 minutes at 98°C and incubating on ice for 5 minutes. Samples were then 
briefly centrifuged and loaded onto Sodium dodecyl sulphate (SDS) containing 
polyacrylamide gel and electrophoresis were performed at 40 milliamperes (mA) per gel 
using 1X electrophoresis buffer.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.2.1. SDS polyacrylamide gel  
The stacking and resolving gel were prepared as per the below tabulated formulation. 
 
 
 
 
 
 
 
 
 
4X Loading buffer 
Components Concentration/Volume 
SDS 5 g 
0.625M Tris-Hcl pH6.8 25 ml 
Glycerol 40 ml 
Bromophenol blue 0.0005 g 
d.H2O 100 ml 
1X Electrophoresis buffer 
Components Concentration/Volume 
SDS 10 g 
Tris 30 g 
Glycine 144 g 
d.H2O 1000 ml 
Separating gel (10 ml) 
Components 8% 10% 15% 
d. H2O 3.87 ml 3.2 ml 1.53 ml 
1.125M Tris, pH8.8 3.33 ml 3.33 ml 3.33 ml 
Acrylamide/Bisacrylamide 
(30%/8%) 
2.66 ml 3.33 ml 5.0 mll 
10% SDS 100 µl 100 µl 100 µl 
TEMED 10  µl 10  µl 10  µl 
10% APS 50  µl 50  µl 50  µl 
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3.2.2.2. Western blotting  
The SDS-polyacrylamide gel separated proteins were then transferred onto the methanol 
activated PVDF membrane (Amersham) using the semi-dry technique in transfer buffer for 1 
hour 30 minutes at 70 mA per gel.  
 
 
 
 
 
 
 
After the transfer, the PVDF membrane was blocked using 5% non-fat dry milk in TBST for 
1.5 hours at RT.  
 
 
 
 
 
 
 
After blocking, the membrane was incubated in a solution of the respective primary antibody 
dissolved in blocking buffer as listed in the appendix for overnight at 4°C. The following day, 
Stacking gel (10 ml) 
Components Concentration/Volume 
d. H2O 6.57 ml 
0.625M Tris, pH6.8 2 ml 
Acrylamide/Bisacrylamide 
(30%/8%) 
1.33 ml 
10% SDS 100 µl 
TEMED 10  µl 
10% APS 100  µl 
Transfer buffer 
Components Concentration/Volume 
Tris 4.85 g 
Glycine 22.51 g 
Methanol 400 ml 
d. H2O Make up to 2000 ml 
10X TBST(pH 7.6)  buffer 
Components Concentration/Volume 
Tris 48.6 g 
NaCl 116 g 
Tween 20 20 ml 
d. H2O 2000 ml 
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the membrane was washed three times with 1X TBST buffer for 10 minutes each time. The 
membrane was then incubated with the respective HRP-conjugated secondary antibody for 1 
hour at RT. The membrane was again washed three times with 1X TBST buffer for 10 minutes 
each time. Then bands on the membrane were visualized using immobilon western 
chemiluminescent HRP substrate as per manufacturer’s instructions for detecting the protein 
expression.   
 
3.2.3. Immunohistochemistry 
 Immunohistochemistry was performed on the slides containing the paraffin-embedded, 
formalin-fixed lung sections from AD (day 7, 14, 21 and 28) and Veh (Day 28) treated mice. 
To deparaffinise, the slides were first warmed at 60°C for 1 to 2 hours and then placed in xylol 
for 10 minutes. Following this, to dehydrate, the slides was placed in descending ethanol 
concentration gradient (99.6%>96% >80%>70%>50%) for 3 minutes each. The slides were 
then washed with 1X fresh PBS for few minutes.  Antigen retrieval was performed by boiling 
the slides at 100°C for 20 minutes in citrate buffer (pH6.0), after which the slides were allowed 
to return to room temperature. This step was repeated for two more times. Then the slides were 
washed three times with 1X PBS for 5 minutes and blocked by incubating it with the blocking 
solution (from AP-fast red or DAB Kit) in a wet chamber for 5 - 10 minutes. The primary 
antibody prepared in 3% BSA were then added to the lung sections and incubated in the wet 
chamber either at RT for 1 hour or at -4°C for overnight. Following this, slides were washed 
four times with 1X PBS for 5 minutes and incubated with biotinylated secondary antibody in a 
wet chamber at RT for 10 minutes. After washing with 1X PBS for three times, the lung 
sections was incubated with enzyme conjugate. After observing the colour development, slides 
were washed following nuclear staining with hämalaun for 45 seconds to a minute. Following 
this, slides were mounted using glycerol mounting medium.  After drying, the sections were 
scanned in digital slide scanner  using NanoZoomer Digital Pathology (NDP) version 2.5.85 
and were analyzed using NDP.view2 software. 
 
3.2.4. Immunofluorescence 
3x10
4
 MLE12 cells were plated in each well of a 8 well chamber slides and left overnight for 
adhering at 37°C with 5% CO2. The following day, the adhered MLE12 cells were treated with 
AD (10µg/ml) or Veh containing medium for 8 hours. The cells were then washed with 1X 
PBS and fixed using 4% Paraformaldehyde for 30 minutes. After washing with 1X PBS, 
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permeabilization was performed with 0.5% Triton X-100. Permeabilized cells were then 
washed and blocked with 3%BSA in PBS for 1 hour at RT. Following this, the cells were 
incubated with primary antibody overnight at 4°C.  The next day, the cells were washed and 
treated with fluorophore conjugated secondary antibody for 1 hour at RT in dark. The cells 
were finally washed with 1X PBS and mounted using VECTASHIELD mounting medium with 
DAPI. The immunofluorescence slides were then analyzed using Leica Application Suite 
Advanced Fluorescence (LAS AF) software, version 4.3, Germany. Similar procedure was 
followed for co-immunofluorescence analysis employing a GFP-transfected plasmid, with the 
transfection being performed 24 hours prior to commencement of the immunofluorescence 
procedure. For immunofluorescence analysis of AECII, same protocol was followed except 
that 24 hours of AD (10 µg/ml) or Veh treatment was carried out.  
 
3.2.5. Immunoprecipitation 
2 mg of Dyna beads M-280 Tosyl activated  per tissue culture dish (10 cm) was taken and 
washed twice with 1 ml of PBS (1X) by placing on the magnetic stand. After washing, the 
beads were resuspended in 58 µl of PBS and 1 µg of antibody (LC3B (ab48394) or p62 
(P0067) or rabbit immunoglobulin G (IgG) (AB-105-C)/ mg of beads were added.  
 
 
 
 
 
To this, buffer A equal to (2/3 volume of PBS + Antibody) was added and incubated overnight 
at RT. The next day, eight hours of AD (10 µg/ml) or vehicle treated MLE12 cells were lysed 
using 400 µl of non-denaturing co-IP lysis buffer. The lysates were kept on ice for 1 hour and 
centrifuged at 15000 rpm for 15 minutes and the supernatant was saved. Total amount of 
protein present in the supernatant of respective lysates were determined using BCA - protein 
assay. Meanwhile, the beads obtained from the overnight incubation were thrice washed 
thoroughly with 1 ml of PBS (1X).  Equal concentration of proteins were then added to IgG or 
Antibody of interest (LC3B or p62) coupled beads (while storing about 20 µl of supernatant as 
input samples) and incubated at 4°C overnight. The following day, the sample tubes were 
placed on the magnetic stand and allowed to stand for five minutes and the supernatant was 
removed. The beads were then washed three times with PBS and resuspended in 20 µl of PBS 
Buffer A 
Components Concentration/Volume 
Ammonium sulphate 3 M 
 PBS - 
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and transferred to a fresh eppendorf tube. Protein loading buffer was added to the beads and 
boiled at 96°C for 10 minutes and the samples were then analyzed using western blotting. 
 
 
 
 
 
 
 
 
 
3.2.6. Mitochondrial-lysosomal fractionation 
The protocol for isolating mitochondrial-lysosomal fraction was adapted from Muquit et al., 
2006. AD (10 µg/ml) or Veh treated MLE12 cells were trypsinized and washed thrice with 
PBS and the resulting pellet was shock frozen in liquid nitrogen and used for isolating 
mitochondrial-lysosomal fraction. All the subsequent steps were performed at 4°C. MLE12 
cells were resuspended in 300 µl of buffer I.  
 
 
 
 
 
 
 
The cells were then disrupted using a dounce homogenizer (20 passes), followed by 15 passes 
with a 20G syringe. The cells were spun down at 830g for 10 minutes and the supernatant S1 
was retained, whereas the pellet was again resuspended in 300 µl of buffer I and dounce 
homogenized again (20 passes) and the cells were spun down at 830g for 10 minutes. The 
supernatant S2 was retained and combined with S1 supernatant and spun down at 16,800g for 
10 minutes. The supernatant (cytoplasmic fraction) was retained and the pellet was 
resuspended in 500 µl of buffer I and spun at 16,800g for 10 minutes. This step was repeated 
three times and all the supernatant were then carefully removed and the pellet (mitochondrial-
lysosomal fraction) was resuspended in 50 - 100 µl of buffer I. The protein concentrations for 
Co-IP lysis buffer 
Components Concentration/Volume 
Tris 50mM 
NaCl 300 mM 
EDTA 5 mM 
TritonX-100 1% 
Sodium azide 0.02% 
PMSF 1% 
Buffer I 
Components Concentration/Volume 
Sucrose 250 mM 
 HEPES 20 mM 
EDTA 3 mM 
PMSF 1% 
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all the fractions were then determined using BCA protein assay and the samples were analyzed 
using western blotting.    
 
3.2.7. Electron spin resonance (ESR) 
For measuring ROS production, duplicate samples of AD (10 µg/ml) or Veh treated MLE12 
cells (10
6
) of five independent treatments were taken and incubated with 1-hydroxy-3-
methoxycarbonyl-2,2,5,5tetramethylpyrrolidine (CMH) (500 µM) spin probe for 30 minutes at  
37°C or with superoxide dismutase conjugated to polyethylene glycol (pSOD) (15 U/ml) for 90 
minutes at 37°C, followed by addition of CMH spin probe and additional incubation for 30 
minutes at 37°C. The samples were then shock frozen and stored in liquid nitrogen. ESR 
measurements for the frozen samples were performed using EMXmicro ESR Spectrometer 
with a g-factor of 2.0063, centre field of 3366.8 G, microwave power of 2.000 mW, sweep 
time of 10 seconds and sweep number of 6. (n = duplicate set of 5 independent treatments). 
 
3.2.8. Statistical analysis 
All data are represented as mean  standard error mean (SEM). The statistical significance was 
calculated by using Mann-Whitney U test in Graphpad Prism 5 software.  Significance is 
indicated *p < 0.5, **p < 0.01, ***p < 0.001.  
 
3.3. Animal tissues 
3.3.1. Preparation of lung homogenates 
With regard to in vivo studies, lung tissue homogenates were used, which had been obtained 
during previously conducted animal experiments (Regierungspräsidium Giessen; GI 20/10 
Nr. 109/2011). In these experiments, mice were transbronchially treated with AD (0.8 mg/kg 
bodyweight) or Veh and lungs were harvested after 7, 14, 21, and 28 days (AD) or 28 days 
(Veh). A small piece of mice lungs ( about 50 mg) of AD (Day 7, 14, 21 and 28) and Veh 
(Day 28) was taken in micro packaging vials containing 1.4 mm and 2.8 mm zirconium oxide 
beads and protein extraction buffer with protease inhibitor. Tissues were then homogenized at 
high speed in Precellys (2 cycles of 20 sec at the speed of 5500 rpm) according to 
manufacturer’s instructions. Samples were then centrifuged for 10 min at 13000 rpm at 4°C 
to pellet the debris. Supernatants were transferred to new tubes and re-centrifuged and the 
resultant supernatant was stored at -80°C until future use. n = 5 mice per group. 
Results
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4. Results 
4.1. AD mediated macroautophagy in AECII: A pro-apoptotic anti-survival 
mechanism 
4.1.1. AD-induced AECII apoptosis is not induced by cathepsin D 
Considering that AD significantly increases the expression of cathepsin D in AECII (Figures 
1.9B, C and E) and cathepsin D mediates apoptosis of AECII in the mouse model of 
Hermansky - Pudlak syndrome (HPS) associated lung fibrosis (Mahavadi et al., 2010), it was 
reasonable to speculate that AD-induced AECII apoptosis might be primed by cathepsin D. 
To analyze this, MLE12 cells were transfected with cathepsin D specific siRNA (CatDsi) and 
non-targeting siRNA (NTsi) for 48 hours and subsequently treated with AD or Veh for 8 
hours. A significant knockdown of cathepsin D was observed under both AD and Veh 
treatment (Figures 4.1A and B). Although a slight reduction in cleaved caspase 3 levels was 
noted under AD treated cathepsin D knockdown condition (Figure 4.1A), it was found to be 
insignificant (Figure 4.1B). A modest increase in cleaved caspase 3 levels observed during 
Veh (NTsi) treatment might have resulted from the stress of transfection, which was 
abrogated upon cathepsin D knockdown (Figures 4.1A and B). This clearly indicates that 
cathepsin D mediates transfection-stress induced apoptosis but not AD-induced AECII 
apoptosis. Further, cathepsin D knockdown did not alter the accumulation of proSP-C nor did 
it influence the lipidation of LC3B following AD treatment (Figures 4.1A, D and E). 
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Figure 4.1: AD-induced alveolar epithelial cell apoptosis is not mediated by Cathepsin D. 
(A) Representative western blot images for cathepsin D, cleaved caspase 3, proSP-C, LC3 and -actin (loading 
control) from 8 hours of AD or Veh treated MLE12 cells transfected with non-targeting siRNA (NTsi) or 
cathepsin D siRNA (CatDsi). n = 3 independent experiments. (B, C, D and E) Densitometry analysis of triple 
target proteins’ blots namely cathepsin D, cleaved caspase 3, proSP-C, LC3 and -actin (loading control) and 
target protein*100/-actin ratio was calculated and represented as bar graphs. **p < 0.01, *p < 0.05, ns - no 
significance. 
 
4.1.2. LC3B mediates AECII apoptosis upon AD treatment 
Since autophagy is suggested be a key player in determining the life and death of cells and 
organisms (Wirawan et al., 2012), we further investigated the role of macroautophagy in AD-
induced AECII apoptosis. To examine this, a knockdown analysis similar to the previously 
explained cathepsin D knockdown was performed in MLE12 cells with LC3B-siRNA 
(LC3si) versus the non-targeting siRNA (NTsi). Under AD or Veh treatment, the knockdown 
of LC3B was evident in MLE12 cells (Figures 4.2A and B). Although no change was noted 
in the level of autophagy substrate p62 in the AD or Veh treated LC3B knocked down 
MLE12 cells (Figures 4.2A and C), a significant decrease in the cleaved caspase 3 level was 
observed under both conditions (Figures 4.2A and D). This implies a pivotal role of LC3B 
(autophagy) in regulating apoptosis of alveolar epithelial cells upon AD treatment. In 
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addition, siRNA against LC3B also attenuates transfection induced apoptosis. AD-induced 
proSP-C accumulation was also abated upon knockdown of LC3B (Figures 4.2A and D). 
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Figure 4.2: LC3B mediate AECII apoptosis in AD treated MLE12 cells. 
(A) Representative western blot images for LC3B, cleaved caspase 3, proSP-C, cathepsin D and -actin (loading 
control) from 8 hours of AD or Veh treated MLE12 cells transfected with non-targeting siRNA (NTsi) or LC3B 
siRNA (LC3si). n = 3 independent experiments. (B, C, D and E) Densitometry analysis of triple target proteins’ 
blots namely LC3B, cleaved caspase 3, proSP-C, cathepsin D and -actin (loading control)) and target 
protein*100/-actin ratio was calculated and represented as bar graphs. **p < 0.01, *p < 0.05, ns - no 
significance. 
 
Upon LC3B knockdown, cathepsin D levels remained unaltered in AD treated MLE12 cells 
reaffirming that AD-induced AECII apoptosis is dependent on LC3B and not cathepsin D.  
Therefore, this analysis shows a pivotal role of macroautophagy, particularly of LC3B in 
mediating AECII cell death and proSP-C accumulation following AD treatment. 
 
4.2. Autophagy flux under AD treatment 
4.2.1. AD induces lysosomal biogenesis in murine alveolar epithelial cells 
In line with the increased expression of cathepsin D observed upon AD treatment, the 
expression of lysosomal-associated membrane protein 1 (LAMP1) and LAMP2 were also 
noted to be prominently upregulated in the lung homogenates of AD treated mice (day 7 - 28) 
(Figures 4.3A, B and C). Immunofluorescence analysis of LAMP1 and LAMP2 revealed an 
intensive staining for LAMP1 and LAMP2 in 8 hours of AD treated cells in contrast to the 
fine punctate staining observed among the Veh treated controls (Figure 4.3D). 
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Figure 4.3: Increased lysosomal biogenesis in mice AECs under AD treatment. 
(A) Western blot analysis of lung homogenates of (left) AD treated mice (day 7, 14) and Veh treated mice (day 
28) and (right) AD treated mice (day 21, 28) and Veh treated mice (day 28) for LAMP1, LAMP2 and -actin 
(loading control). n = 5 mice per group. (B, C) Densitometry analysis of the target proteins’ blots and target 
protein*100/-actin ratio was calculated and represented as a bar graph. **p < 0.01, *p < 0.05, ns - no 
significance. (D) Immunofluorescence analysis of 8 hours of AD or Veh treated MLE12 cells for LAMP1 and 
LAMP2 (green). Nuclei are stained with DAPI (blue). Arrows indicate increased swollen LAMP1 and LAMP2 
staining in the perinuclear regions of AD treated MLE12 cells versus the Veh. n = 3 independent experiements. 
Scale bar = 10 µm. 
 
It is hence obvious, AD does not only increase the production of lysosomal enzymes viz 
cathepsin D, but also induces the lysosomal biogenesis per se. 
 
4.2.2. Increase in autophagy flux under AD treatment 
Since AD-induced fusion of autophagosomes with lysosomes was evident in MLE12 cells, 
the autophagy flux under AD treatment was then analysed using the vacuolar ATPase (V-
ATPase) inhibitor, Bafilomycin A1 (Baf A1). MLE12 cells were pre-treated with Baf A1 
(100 nM) for 1 hour, prior to the treatment with 8 hours of AD or Veh. The vacuolar 
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cytopathology induced by AD in the MLE12 cells was found to be completely abrogated 
upon bafilomycin A1 pre-treatment (Figure 4.4A). A similar result was also obtained upon 
co-treating MLE12 cells with Baf A1 and AD (Figure 4.4B). This is in accordance with the 
observation of Morissette et al., 2009, who demonstrated that bafilomycin A1 inhibits 
vacuolization and the cellular uptake of AD. Thus, another autophagy inhibitor, Chloroquine 
(CQ) (10 µg/ml and 30 µg/ml), was used to analyze flux in MLE12 cells under AD treatment. 
A significant increase in LCBII level was evident in CQ pre-treated MLE12 cells, followed 
by AD treatment, than AD treated MLE12 cells alone (Figure 4.4C). From this result, it is 
apparent that AD increases autophagy flux in MLE12 cells.  
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Figure 4.4: AD increases autophagy flux in MLE12 cells. 
(A, B) Phase-contrast images of MLE12 cells pre-treated or co-treated with Baf A1, prior to 8 hours of AD or 
Veh treatment. (C) Representative western blot images for LC3B and -actin (loading control) from lysates 
obtained from 4 hours of CQ pre-treated MLE12 cells, followed by 8 hours of AD or Veh treatment. n = 3 
independent experiments. Densitometry analysis of the target proteins’ blots and target protein*100/-actin ratio 
was calculated and represented as a bar graph. . ***p < 0.001,**p < 0.01, *p < 0.05, ns - no significance. 
 
4.3. Mitophagy in murine model of AD-induced pulmonary fibrosis 
4.3.1. AD escalates ROS production in mice AECs 
In order to determine if AD increases ROS production (superoxide and peroxynitrite 
radicals), MLE12 cells were treated with AD (10 µg/ml) or Veh for 8 hours and incubated 
with the CMH spin probe. To determine the amount of superoxide radicals (O2
.-
) in particular, 
a pre-incubation step with pSOD was performed prior to incubation with the CMH spin probe 
and later the ESR were measured for the stored shock frozen samples. The ESR spectra were 
obtained as represented (Figures 4.5A, B, C and D) for CMH+AD, CMH+Veh, 
CMH+pSOD+AD and CMH+pSOD+Veh treated samples respectively. 
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Figure 4.5. Elevated ROS production in AD treated mice alveolar epithelial cell line. 
(A, B, C and D). Representative ESR spectra obtained for 8 hours of AD or Veh treated MLE12 cells (105 
cells/300 µl) probed with CMH and CMH + pSOD respectively. n = duplicate set of 5 samples per group. The 
green line represents zero intensity. X-axis: Magnetic field (G), Y-axis: Intensity (a.u). a.u = arbitrary units. (E). 
Graphical representation of ROS production in CMH probed AD or Veh treated MLE12 cells by calculating the 
average ESR spectral intensities. ***p < 0.0001. (F). Graphical representation of superoxide radical (O2
.-) 
production in AD or Veh treated MLE12 cells by calculating the difference between the average ESR spectral 
intensities obtained from CMH and CMH + pSOD probed AD or Veh treated MLE12 cells. ***p < 0.0001.  
 
Upon averaging the spectral intensities obtained from CMH+AD and CMH+Veh treated 
samples, an increased production of ROS was evident in MLE12 upon AD treatment (Figure 
4.5E), and then a remarkable rise in the production of superoxide radicals (O2
.-
) was also 
noted in AD treated MLE12 cells (Figure 4.5F). These results thus prove the inherent ability 
of AD to generate ROS in a murine alveolar epithelial cell line. 
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4.3.2. AD increases mitochondrial mass in murine AECII 
Since significant increase in ROS production was observed in AD treated MLE12 cells and as 
mitochondria are a major source of ROS production, we further investigated if increased ROS 
may be attributed to altered mitochondrial homeostasis under conditions of AD treatment. 
Hence, we first examined the protein expression of the mitochondrial protein, Cytochrome c 
oxidase subunit IV (COX IV) in the lung homogenates of day 7, 14, 21 and 28 of the AD and 
day 28 of Veh treated C57/Bl6 mice. A significant upregulation in the expression of COX IV 
(~ 2 to 2.5-fold) was observed starting day 7 after AD treatment (Figures. 4.6A and B). 
 
 
 
 
 
 
 
15 COX IV
MW
(kDa)
β-actin
40
AD D7 AD D14 Veh D28 Veh D 28AD D21 AD D28
A.
A
D
 N
Ts
i
A
D
 C
at
D
si
V
eh
 N
Ts
i
V
eh
 C
at
D
si A
D
V
eh
0
50
100
150
AD
NTsi
AD
CatDsi
Veh
CatDsi
Veh
NTsi
AD
ID
V
 
%
 o
f ß
-a
ct
in
nsns
**
proSP-C
Veh
ns
A
D
 N
Ts
i
A
D
 C
at
D
si
V
eh
 N
Ts
i
V
eh
 C
at
D
si A
D
V
eh
0
50
100
150
AD
NTsi
AD
CatDsi
Veh
CatDsi
Veh
NTsi
AD
ID
V
 
%
 o
f ß
-a
ct
in
ns
ns
**
LC3BII
Veh
*
A
D
 N
Ts
i
A
D
 L
C
3B
si
V
eh
 N
Ts
i
V
eh
 L
C
3B
si A
D
V
eh
0
50
100
150
AD
NTsi
AD
CatDsi
Veh
CatDsi
Veh
NTsi
AD
ID
V
 
%
 o
f ß
-a
ct
in
**
ns
**
Cleaved caspase 3
Veh
ns
B. C.
A
D
 D
7
A
D
 D
14
A
D
 D
21
A
D
 D
 2
8
V
eh
 D
28
0
50
100
150
ID
V
%
 o
f 
ß
-a
c
ti
n
*
ID
V
 
%
 o
f 
ß-
a
ct
in
COX IV
AD D7     AD D14     AD D21    AD D28    Veh D28
*
**
CO
X
 IV
p
ro
S
P-
C
AD D7 AD D14 AD D21 AD D28 Veh D28
C.
Results
 
54 
 
 
 
            
                                 
 
 
 
               
 
 
 
A
D
 8
h
A
D
 1
6h
A
D
 2
4h
V
eh
 D
24
0
50
100
150
200
ID
V
%
 o
f 
ß
-a
c
ti
n
ns
ID
V
 
%
 o
f ß
-a
ct
in
AD 8h          AD 16h         AD 24h        Veh 24h
COXIV
*
ns
A
D
 
V
eh
0
50
100
150
ID
V
%
 o
f 
ß
-a
c
ti
n
*
ID
V
 
%
 o
f G
A
PD
H
AD                                      Veh
COX IV
D. E.
AD Veh
AECIIMW
(kDa)
COX IV
15
proSP-C
25
GAPDH35
AD
8            16           24            24
MW
(kDa) Veh
MLE12
Hours
15 COX IV
β-actin
40
G. H.
VehAD
AECII
CO
X
 IV
p
ro
SP
-C
F.
E
VehAD
AECII
C
O
X
 IV
p
ro
SP
-C
A
D
 8
h
A
D
 1
6h
A
D
 2
4h
V
eh
 D
24
0
50
100
150
200
ID
V
%
 o
f 
ß
-a
c
ti
n
ns
ID
V
 
%
 o
f ß
-a
ct
in
AD 8h          AD 16h         AD 24h        Veh 24h
COXIV
*
ns
A
D
 
V
eh
0
50
100
150
ID
V
%
 o
f 
ß
-a
c
ti
n
*
ID
V
 
%
 o
f G
A
PD
H
AD                                      Veh
COX IV
D. E.
AD Veh
AECIIMW
(kDa)
COX IV
15
proSP-C
25
GAPDH35
AD
8            16           24            24
MW
(kDa) Veh
MLE12
Hours
15 COX IV
β-actin
40
G. H.
Results
 
55 
 
           
 
 
Figure 4.6. Increase in mitochondrial mass in murine alveolar epithelial cells after AD treatment. 
(A) Western blot analysis of lung homogenates of (left) AD treated mice (day 7, 14) and Veh treated mice (day 
28) and (right) AD treated mice (day 21, 28) and Veh treated mice (day 28) for COX IV and -actin (loading 
control). n = 5 mice per group. (B) Densitometry analysis of the COX IV and -actin blots and COX IV*100/-
actin ratio was calculated and represented as a bar graph. *p < 0.05. (C) Immunohistochemical analysis of serial 
lung sections of AD (day 7, 14, 21 and 28) and Veh (day 28) treated mice for COX IV and proSP-C. Arrows 
indicate AECII showing increased COX IV expression from day 7 of AD treatment. n = 5 mice per group. Scale 
bar = 50 µm. Original magnification: x400. (D) Representative western blot images for COX IV, proSP-C and 
GAPDH (loading control) from 24 hours of AD or Veh treated C57Bl/6 murine AECII’ lysates. n = 3 
independent experiments. (E) Densitometry analysis of triplicate blots of COX IV and GAPDH and COX 
IV*100/GAPDH ratio was calculated and represented as a bar graph. *p < 0.05. (F) Immunofluorescence 
analysis of 24 hours of AD or Veh treated murine AECII for COX IV (red). Nuclei are stained with DAPI 
(blue). Arrows indicate cells showing increased COX IV expression under AD treatment. n = 3 independent 
experiments. Scale bar = 10 µm.  (G) Representative western blot images for COX IV and -actin (loading 
control) from 8, 16 and 24 hours of AD and 24 hours of Veh treated MLE12 cells’ lysates. n = 3 independent 
experiments. (H) Densitometry analysis of triplicate blots of COX IV and -actin and COX IV*100/-actin ratio 
was calculated and represented as a bar graph. *p < 0.05, ns = no significance. (I) Immunofluorescence analysis 
of 8 hours of AD or Veh treated MLE12 cells for COX IV (red). Nuclei are stained with DAPI (blue). Arrows 
indicate increased COX IV expression in the perinuclear region and on the margins of vacuoles under AD 
treatment. n = 3 independent experiments. Scale bar = 10 µm. 
 
Immunohistochemical analysis for COX IV and proSP-C (AECII marker) performed on serial 
lung sections revealed an increased localization of COX IV to AECII in AD treated (day 7, 14, 
21 and 28) mice compared to the Veh treated (day 28) control mice (Figure 4.6C). In order to 
find if COX IV upregulation is substantial in the alveolar epithelium, AECII from C57/Bl6 
mice were isolated and treated with 10 µg/ml of AD or Veh for 24 hours and analysed for the 
expression of COX IV. In line with the AD treated lung homogenates, COX IV expression was 
significantly increased (~ 2-fold) in AD treated AECII in vitro (Figures 4.6D and E). Similarly, 
immunoblot analysis of MLE12 cells treated with same concentration of AD for 24 hours also 
demonstrated a prominent increase (~ 1.5-fold) in COX IV expression (Figures 4.7G and H). 
Under AD treatment, the immunofluorescence analysis of murine AECII and MLE12 cells 
showed marked increase in COX IV expression compared to the Veh (Figures 4.6F). In 
particular, in AD treated MLE12 cells, COX IV were partly observed to be localised in the 
perinuclear region, especially on the margins of the giant vacuolar structures induced by AD 
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(Figure 4.6I).  Altogether, the data point towards increased mitochondrial biogenesis in AECII 
following AD treatment. 
 
4.3.3. AD induces differential expression of mitophagy proteins in murine 
AECII 
It has been reported that AD induces autophagy (Mahavadi et al., 2015) and we now show 
that AD treated alveolar epithelial cells display excessive ROS production and mitochondrial 
biogenesis. We hence asked if AD promotes mitochondrial autophagy/mitophagy. Therefore, 
the expression level of different mitophagy proteins Bnip3L, Bnip3, p62, NBR1, ATG12-
ATG5 and ATG7 was investigated. Western blot analysis of the AD (day 7, 14, 21 and 28) 
and Veh (day 28) treated lung homogenates revealed no significant difference in the 
expression of mitophagy receptor proteins BNIP3L (homodimer and monomer) and BNIP3 
(Figures 4.7A, B, C and D). In concordance, there was unaltered Bnip3L (homodimer and 
monomer) and Bnip3 protein expression in the AD or Veh treated isolated murine AECII 
(Figures 4.8A, B, C and D) and MLE12 cells (Figures 4.9 A, B, C and D).   
The expression of autophagy adaptor proteins p62 and NBR1 was then evaluated in AD 
treated mice lung homogenates. Apart from acting as substrates for autophagy, both of these 
proteins also serve as cargo receptors for ubiquitinated substrates. As reported previously 
(Mahavadi et al., 2015), a significantly increased expression of p62 (~ 1.5 to 2-fold) was 
observed from day 14 of AD treatment in the lung homogenates of C57Bl/6 mice (Figures 
4.7A and B). Immunohistochemical analysis for p62 and proSP-C (AECII marker) on the 
serial mice lung sections revealed increased localization of p62 to AECII in the lung sections 
of AD treated (day 7, 14, 21 and 28) mice compared to the Veh treated (day 28) control mice 
(Figure 4.7I). In complete agreement, western blot analysis of 24 hours of AD treated murine 
AECII also demonstrated a significant rise (~ 2-fold) in the expression of p62 (Figures 4.8A 
and E). Likewise, AD (8, 18 and 24 hours) treated MLE12 cells also exhibited an increase (~ 
2 to 2.5-fold) in p62 expression versus the Veh (Figures 4.9A and E). In addition, the 
expression of NBR1 protein was found to be significantly increased (~ 2 to 2.5-fold) in the 
lung homogenates of AD (day 14, 21 and 28) treated mice (Figures. 4.7A and F). However, 
the expression of NBR1 remained unaltered in AD and Veh treated murine AECII (Figures 
4.8A and F) and MLE12 cells in vitro (Figures 4.9A and F). The increase in NBR1 protein 
levels in AD treated mice lung homogenates but not in AD treated murine AECII and MLE12 
cells in vitro could be attributed to the diverse cell population present within the lung.  
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In addition, the expression of conventional macroautophagy proteins, ATG12-ATG5 and 
ATG7 was also analyzed, as deficiency of these proteins has been proven to induce 
mitochondrial defects and hinder the clearance of damaged mitochondria (Wu et al., 2009, 
Liu et al., 2012). Immunoblot analysis of the AD treated mice lung homogenates, murine 
AECII and MLE12 treated with AD in vitro displayed proficient increase in the expression of 
ATG12-ATG5 (~ 1.5-fold) in comparison to the Veh treated controls (Figures 4.7A and G, 
4.8A and G, 4.9A and G). Similar to AD-induced ATG12-ATG5 expression, immunoblot 
analysis of AD (day 7, 21 and 28) treated mice lung homogenates exhibited significant 
upregulation (~ 2-fold) of ATG7 expression versus the Veh (Figures 4.7A and H). 
Immunohistochemical analysis for ATG7 and proSP-C (AECII marker) on the serial lung 
sections revealed an increased staining of ATG7 in AECII in lung sections of AD treated 
(day 7, 14, 21 and 28) mice compared to the Veh treated (day 28) control mice (Figure 4.7J).  
In line with this, in vitro AD treated murine AECII (Figure 4.8A and H) and AD treated 
MLE12 cells (Figures 4.9A and H) also showed a significant increase (~ 2 and ~ 1.5-fold 
respectively) in the ATG7 expression after 24 hours.  
Thus, these results collectively imply unaltered expression of the mitophagy receptor proteins 
Bnip3L & Bnip3 and the cargo receptor protein NBR1, but an increased synthesis of 
autophagy adaptor protein p62 and other mitophagy proteins such as ATG12-ATG5 and 
ATG7 in murine AECII following AD treatment in vivo and in vitro. 
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Figure 4.7. Differential expression of mitophagy proteins in AD treated mice lung tissues. 
(A) Western blot analysis of lung homogenates of (left) AD treated mice (day 7, 14) and Veh treated mice (day 
28) and (right) AD treated mice (day 21, 28) and Veh treated mice (day 28) for Bnip3L (homodimer and 
monomer), Bnip3, p62, NBR1, ATG12-ATG5, ATG7 and -actin (loading control). n = 5 mice per group. (B, 
C, D, E, F, G, H) Densitometry analysis of the target proteins’ blots namely Bnip3L (homodimer and 
monomer), Bnip3, p62, NBR1, ATG12-ATG5, ATG7 and -actin (loading control) and target protein*100/-
actin ratio was calculated and represented as bar graphs. **p < 0.01, *p < 0.05, ns - no significance. (I) 
Immunohistochemical analysis of serial lung sections of AD (day 7, 14, 21 and 28) and Veh (day 28) treated 
mice for p62 and proSP-C. Arrows indicate AECII showing increased p62 expression from day 7 of AD 
treatment. n = 5 mice per group. Scale bar = 50 µm. Original magnification: x400 (J) Immunohistochemical 
analysis of serial lung sections of AD (day 7, 14, 21 and 28) and Veh (day 28) treated mice for ATG7 and 
proSP-C. Arrows indicate AECII showing increased ATG7 expression from day 7 of AD treatment. n = 5 mice 
per group. Scale bar = 50 µm. Original magnification: x400. 
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Figure 4.8. Differential expression of mitophagy proteins in  AD treated AECII.  
(A) Representative western blot images for Bnip3L (homodimer & monomer), Bnip3, p62, NBR1, ATG12-
ATG5, ATG7, proSP-C and GAPDH (loading control) from 24 hours of AD or Veh treated AECII isolated from 
C57Bl/6 mice. n = 3 independent experiments. (B, C, D, E, F, G and H) Densitometry analysis of the triplicate 
blots of the target proteins viz Bnip3L (homodimer & monomer), Bnip3, p62, NBR1, ATG12-ATG5, ATG7 and 
GAPDH (loading control) and target protein*100/GAPDH ratio was calculated and represented as bar graphs. 
**p < 0.01,*p < 0.05, ns - no significance. 
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Figure 4.9. Differential expression of mitophagy proteins in AD treated MLE12 cells.  
(A) Representative western blot images for Bnip3L (homodimer & monomer), Bnip3, p62, NBR1, ATG12-
ATG5, ATG7, proSP-C and -actin (loading control) from AD (8, 16 and 24 hours) and Veh (24 hours) treated 
MLE12 cells. n = 3 independent experiments. (B, C, D, E, F, G and H) Densitometry analysis of the triplicate 
blots of the target proteins viz Bnip3L (homodimer & monomer), Bnip3, p62, NBR1, ATG12-ATG5, ATG7 and 
-actin (loading control) and target protein*100/-actin ratio was calculated and represented as bar graphs. **p 
< 0.01,*p < 0.05, ns - no significance. 
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4.3.4. AD initiates mitophagy via lysine 63-linked ubiquitin chains and p62 in 
murine AECII 
The selective autophagy protein p62 plays a key role in aggregating dysfunctional 
mitochondria and delivering it for autophagic degradation (Geisler et al., 2010). In an attempt 
to figure out if AD-induced p62 accumulation promotes mitophagy,  immunofluorescence (IF) 
analysis of p62 was performed in AD versus Veh treated murine AECII (24 hours) and MLE12 
cells (8 hours). Since the ubiquitin associated (UBA) domain of p62 exhibits exclusively strong 
binding affinity towards K63-linked ubiquitin chains (ubiquitin.K63) and the Phox and Bem 1 
(PB1) domain of p62 boosts interaction with NBR1  (Johansen and Lamark, 2011; Kirkin et 
al., 2009), the expression and distribution pattern of NBR1 and ubiquitin.K63 were also 
analyzed.   
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Figure 4.10. Selective autophagy proteins viz p62, NBR1 and ubiquitin.K63 in AD treated AECII and 
MLE12 cells.  
(A) Immunofluorescence analysis of 24 hours of AD or Veh treated murine AECII for p62 (red), NBR1 (red) 
ubiquitin.K63 (red) and proSP-C (red) (AECII marker). Nuclei are stained with DAPI (blue). Arrows indicate 
cells showing increased expression of respective protein under AD treatment. n = 3 independent experiments. 
Scale bar = 10 µm.  (B) Immunofluorescence analysis of 8 hours of AD or Veh treated MLE12 cells for p62 (red), 
NBR1 (red) and ubiquitin.K63 (red). Nuclei are stained with DAPI (blue). Arrows indicate cells showing 
perinuclear clustering of the respective protein under AD treatment. n = 3 independent experiments. Scale bar = 
10 µm. 
 
Immunofluorescence analysis of AD treated murine AECII and MLE12 cells in vitro revealed 
strong punctate staining of p62 and ubiquitin.K63 (in spite of the ubiquitin.K63 antibody 
staining the background in AECII) in comparison to a very faint diffused staining observed 
among the Veh treated controls (Figure 4.10A). Additionally, MLE12 cells displayed increased 
perinuclear clustering of p62 and ubiquitin.K63 under AD treatment (Figure 4.10). In 
accordance with the observation of unaltered  expression of NBR1 in the western blot analysis 
of AD treated AECII and MLE12 cell lysates (Figures 4.8A and 4.9A), no observable 
differences in expression were visualized between the AD and Veh treated AECII and MLE12 
cells as shown in figures 4.10A and B.  Both AD and Veh treated cell types mostly displayed a 
punctate staining for NBR1.   
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In order to identify if p62, NBR1 or ubiquitin.K63 are targeted to the autophagosomes under 
AD treatment, MLE12 cells were transfected with GFP-LC3B plasmid overnight, followed by 
treatment with AD or Veh for 8 hours. Co-immunofluorescence analysis was then performed 
using antibodies against p62, NBR1 or ubiquitin.K63. AD treatment of the GFP-LC3B 
transfected MLE12 cells resulted in the characteristic GFP-LC3B puncta and  they were found 
encircling the AD-induced vacuoles in contrast to the diffused staining observed among the 
Veh treated cells.  Co-immunofluorescence analysis displayed increased co-localization of 
GFP-LC3B with p62 under AD treatment as compared to the vehicle treated cells (Figure 
4.11A). In Veh treated cells, co-localization between GFP-LC3 and p62 was observed, albeit at 
lower levels as p62 is destined to undergo autophagy under normal conditions. In full support, 
primary AECII treated with AD for 24 hours in vitro also exhibited significant co-localization 
of LC3B and p62 (Figure 4.11B).  
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Figure 4.11. Targeting of ubiquitin.K63 and p62 to the autophagosomes in AD treated AECs. 
(A) Co-immunofluorescence analysis of 8 hours of AD or Veh treated GFP-LC3B (green) transfected MLE12 
cells for p62 (red). Nuclei are stained with DAPI (blue). Arrows indicate the co-localization (yellow) of p62 with 
GFP-LC3B under AD treatment. n = 3 independent experiments. Scale bar = 10 µm.  (B) Co-immunofluorescence 
analysis of 24 hours of AD or Veh treated murine AECII for LC3B (green) and p62 (red). Nuclei are stained with 
DAPI (blue). Arrows indicate the co-localization (yellow) of LC3B with p62 under AD treatment. n = 3 
independent experiments. Scale bar = 10 µm. (C) Western blot images for LC3B, p62, Bnip3L (homodimer and 
Monomer) and Bnip3 from 8 hours of AD or Veh treated MLE12 cells’ lysates immunoprecipitated with LC3B or 
Immunoglobulin G (IgG) antibodies. (D) Western blot images for p62 and LC3B from 8 hours of AD or Veh 
treated MLE12 cells’ lysates immunoprecipitated with p62 or Immunoglobulin G (IgG) antibodies. (E) Co-
immunofluorescence analysis of 8 hours of AD or Veh treated GFP-LC3B (green) transfected MLE12 cells for 
NBR1 (red). Nuclei are stained with DAPI (blue). n = 3 technical replicates. Scale bar = 10 µm. (F) Co-
immunofluorescence analysis of 8 hours of AD or Veh treated GFP-LC3B (green) transfected MLE12 cells for 
ubiquitin.K63 (red). Nuclei are stained with DAPI (blue). Arrows indicate the co-localization (yellow) of 
ubiquitin.K63 with GFP-LC3B (yellow) under AD treatment. n = 3 independent experiments. Scale bar = 10 µm.  
 
In addition, co-immunoprecipitation analysis revealed significant pull down of p62 with LC3B 
antibody in the AD treated MLE12 cells and vice versa (Figure 4.11C and D). Interestingly, co-
immunoprecipitation experiments with LC3B antibody did not pull down Bnip3L or Bnip3 
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upon AD treatment in spite of higher concentration of the respective proteins being present in 
the input (Figure 4.11C). This re-emphasizes the strong interaction between p62 and LC3B 
under AD treatment. In case of NBR1, a fraction of NBR1 protein was found to be very weakly 
co-localizing with GFP-LC3B in the AD treated MLE12 cells (Figure 4.11E), whereas a 
prominent co-localization was observed between GFP-LC3B and ubiquitin.K63 in MLE12 
cells upon AD treatment that was not observed in Veh treated GFP-LC3B transfected MLE12 
cells (Figure 4.11F). Therefore, these experiments confirm that AD-induced ubiquitin.K63 and 
p62 are targeted to autophagosomes.  
In our further attempts to analyze if the damaged mitochondria are targeted to autophagosomes 
under conditions of AD treatment, we performed immunofluorescence analysis for COXIV in 
GFP-LC3B transfected AD treated MLE12 cells and asked if COXIV co-localizes with GFP-
LC3B. Interestingly, we observed a prominent increase in co-localization signals for COX IV 
with GFP-LC3B compared to that of the Veh treated controls (Figure 4.12A). This to us 
indicated that AD treatment targets mitochondria to the autophagosomes. This further led to the 
speculation that AD-induced dysfunctional mitochondria are probably targeted to the 
autophagosomes via p62.  In order to test this, we isolated cytoplasmic and mitochondrial-
lysosomal (ML) subcellular fractions from 8 hours of AD or Veh treated MLE12 cells using 
the protocol adapted from Muquit et al., (Muqit et al., 2006) and examined for the presence of 
p62, LC3B I and II, Bnip3L and Bnip3. 
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Figure 4.12. Mitochondria are targeted to the autophagosomes via p62 in AD treated MLE12 cells. 
(A) Co-immunofluorescence analysis of 8 hours of AD or Veh treated GFP-LC3B (green) transfected MLE12 
cells for COX IV (red). Nuclei are stained with DAPI (blue). Arrows indicate the co-localization (yellow) of COX 
IV with GFP-LC3B under AD treatment. n = 3 independent experiments. Scale bar = 10 µm. (B) Representative 
western blot images for Bnip3L (Monomer), Bnip3, p62, LC3B, COX IV (Mitochondrial marker), LAMP1 
(Lysosomal marker) and GAPDH (cytoplasmic marker) of the cytoplasmic and mitochondrial-lysosomal (Mito-
lyso) fractions from 8 hours of AD or Veh treated MLE12 cells. n = 3 technical replicates. 
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In coherence with our previous results, p62 and LC3BII were found to be significantly 
increased in the mitochondrial-lysosomal fraction of AD treated MLE12 cells, while Bnip3L 
and Bnip3 remained (Figure 4.12B). Hence, from these results we concluded that p62 plays a 
pivotal role in targeting dysfunctional mitochondria to the autophagosomes upon AD 
treatment. 
 
4.3.5. Mitochondria entrapped autophagosomes are targeted to lysosomes in 
AD treated murine AECII in vitro. 
To further verify whether ubiquitin.K63 and p62 tagged mitochondria trapped within the 
autophagosomes are targeted to the lysosomes,  co-immunofluorescence analysis of p62, 
NBR1, ubiquitin.K63 and COX IV were performed with the lysosomal marker, lysosomal-
associated membrane protein 1 (LAMP-1) after 8 hours of AD or Veh treatment of MLE12 
cells. This analysis revealed prominent and increased co-localization of p62, ubiquitin.K63 and 
COX IV with LAMP-1 at many foci in the AD treated MLE12 cells, a finding that was not 
observed among the Veh treated controls (Figures 4.13A, D and E). Similar to our previous 
observations very few NBR1 proteins were found to be localized along the margins of LAMP-
1 positive staining in the MLE12 cells following AD treatment (Figure 4.13C).  Co-localization 
of p62 and COX IV with another lysosomal marker, cathepsin D was examined in 24 hours of 
AD, Veh treated murine AECII in vitro, to reconfirm their targeting to the lysosomes. Like the 
MLE12 cells, AD treated primary AECII also exhibited significantly increased co-localization 
of p62 and COX IV with cathepsin D (Figures 4.13B and F).  
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Figure 4.13. Mitochondria entrapped autophagosomes are targeted to lysosomes in AD treated murine 
AECII in vitro. 
(A) Co-immunofluorescence analysis of 8 hours of AD or Veh treated MLE12 cells for LAMP-1 (green) and p62 
(red). Nuclei are stained with DAPI (blue). Arrows indicate the co-localization (yellow) of p62 with LAMP-1 
under AD treatment. n = 3 independent experiments. Scale bar = 10 µm. (B) Co-immunofluorescence analysis of 
24 hours of AD or Veh treated murine AECII for cathepsin D (Cat D) (green) and p62 (red). Nuclei are stained 
with DAPI (blue). Arrows indicate the co-localization (yellow) of Cat D with p62 under AD treatment. n = 3 
independent experiments. Scale bar = 10 µm. (C) Co-immunofluorescence analysis of 8 hours of AD or Veh 
treated MLE12 cells for LAMP-1 (green) and NBR1 (red). Nuclei are stained with DAPI (blue). n = 3 independent 
experiments. Scale bar = 10 µm. (D) Co-immunofluorescence analysis of 8 hours of AD or Veh treated MLE12 
cells for LAMP-1 (green) and ubiquitin.K63 (red). Nuclei are stained with DAPI (blue). Arrows indicate the co-
localization (yellow) of ubiquitin.K63 with LAMP-1 under AD treatment. n = 3 independent experiments. Scale 
bar = 10 µm. (E) Co-immunofluorescence analysis of 8 hours of AD or Veh treated MLE12 cells for LAMP-1 
(green) and COX  IV (red). Nuclei are stained with DAPI (blue). Arrows indicate the co-localization (yellow) of 
COX IV with LAMP-1 under AD treatment. n = 3 independent experiments. Scale bar = 10 µm. (D) Co-
immunofluorescence analysis of 24 hours of AD or Veh treated murine AECII for cathepsin D (Cat D) (green) and 
COX IV (red). Nuclei are stained with DAPI (blue). Arrows indicate the co-localization (yellow) of Cat D with 
COX IV under AD treatment. n = 3 independent experiments. Scale bar = 10 µm. 
Therefore, results of these analyses validate our hypothesis that mitochondria that are trapped 
within the autophagosomes are targeted to lysosomes following AD treatment.  
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4.3.6. Inhibition of AD-induced mitophagy or oxidative stress alters LC3B 
lipidation in murine AECII in vitro 
In order to further decipher the role of mitophagy and oxidative stress in driving AD-induced 
autophagy, we exploited the use of mdivi-1, a mitochondrial division inhibitor and N-acetyl-L-
cysteine (NAC), an antioxidant. Mdivi-1 is a pharmacological inhibitor that prevents 
mitochondrial fission by inhibiting Drp-1 (Mizumura et al., 2014). Division of the damaged 
mitochondria from its healthy counterpart is a pre-requisite for initiation of mitophagy (Ding 
and Yin, 2012), hence prevention of fission prevents mitophagy. Co-treatment of MLE12 cells 
with AD and mdivi-1 (20 µM) for 4 hours displayed proficient downregulation in the lipidation 
of LC3B, i.e. less LC3BII synthesis and a prominent decrease in annexin V staining was 
observed in MLE12 cells under AD + mdivi-1 treatment  (Figures 4.15A, B and C). Thus, the 
prevention of AD driven mitophagy inhibits apoptosis. A significant downregulation in LC3B 
lipidation was noted in MLE12 cells co-treated with AD and NAC (2 mM) for 4 hours, too.  
(Figures 4.15 D, and E) Similarly, a drastic reduction in  LC3BII were observed in murine 
AECII co-treated with AD and NAC (2 mM) for 24 hours  (Figures 4.15 F and G). It is already 
known that the LC3B knockdown under AD treatment also prevents apoptosis of AECII 
(Figures 4.2A and D). Taken together, these observations suggest prevention of either AD 
driven aberrant mitophagy or oxidative stress drastically reduces LC3B lipidation and 
apoptosis.   
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Figure 4.14. Reduced LC3B lipidation in AD treated AECII upon mitophagy or oxidative stress 
inhibition. 
(A) Representative western blot images for LC3B and -actin (loading control) from 4 hours of mdivi-1 (20 
µM) and AD or Veh co-treated MLE12 cells’ lysates. n = 3 independent experiments. (B) Densitometry analysis 
of the triplicate blots of LC3BII and -actin (loading control) and LC3BII*100/-actin ratio was calculated and 
represented as a bar graph. **p < 0.01, ns - no significance. (C) Immunofluorescence analysis of 4 hours of AD 
+ DMSO, AD + mdivi-1or Veh+Veh treated MLE12 cells for Annexin V (red). Nuclei are stained with DAPI 
(blue). Arrows indicate increased annexin V staining under AD treatment. Scale bar = 10 µm. (D) 
Representative western blot images for LC3B and -actin (loading control) from 1 and 4 hours of NAC (2 mM) 
and AD or Veh co-treated MLE12 cells’ lysates. n = 3 independent experiments. (E) Densitometry analysis of 
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the triplicate blots of LC3BII and -actin (loading control) and LC3BII*100/-actin ratio was calculated and 
represented as a bar graph. **p < 0.01, *p < 0.05, ns - no significance. (F) Representative western blot images 
for LC3B and GAPDH (loading control) from 24 hours of N-acetyl-L-Cysteine (NAC) (2 mM) and AD or Veh 
co-treated C57Bl/6 murine AECIIs’ lysates. n = 3 technical replicates. (G) Densitometry analysis of the 
triplicate blots of LC3BII and GAPDH (loading control) and LC3BII*100/GAPDH ratio was calculated and 
represented as a bar graph. **p < 0.01, *p < 0.05.  
 
4.4. Anti-oxidative response in murine model of AD-induced pulmonary 
fibrosis 
4.4.1. AD induces HO-1 production in response to increased oxidative 
stress in AD treated murine AECII 
It is evident from the current (Figure 4.5) and previous studies (Nicolescu et al., 2008, Bolt et 
al., 2001) that AD drastically increases oxidative stress. In order to analyze the counteracting 
anti-oxidative response under AD treatment conditions, the expression of a major antioxidant 
protein, Heme oxygenase-1 (HO-1) was analyzed. Western blot analysis of the lung 
homogenates of day 7, 14, 21 and 28 of AD and day 28 of Veh treated C57/Bl6 mice revealed 
an increase in HO-1 since day 7 of AD treatment, with a significant 24-fold increase at day 14 
of AD treatment (Figures. 4.15A and B), after which it was gradually decreased. The 
immunohistochemical analysis for HO-1 and proSP-C  performed on the serial lung sections 
revealed increased localization of HO-1 to AECII in AD treated (day 7, 14, 21 and 28) mice 
compared to the Veh treated (day 28) controls (Figure 4.15 C). In line with the AD treated lung 
homogenates, HO-1 expression was prominently upregulated (~ 2-fold) in AD treated isolated 
murine AECII (Figures 4.15D and E). 
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Figure 4.15. Increased HO-1 expression in AD treated mice lungs, primary AECII and MLE12 cells.  
(A) Western blot analysis of lung homogenates of (left) AD treated mice (day 7, 14) and Veh treated mice (day 
28) and (right) AD treated mice (day 21, 28) and Veh treated mice (day 28) for HO-1 and -actin (loading 
control). n = 5 mice per group. (B) Densitometry analysis of the HO-1 and -actin blots and HO-1*100/-actin 
ratio was calculated and represented as a bar graph. **p < 0.01. (C) Immunohistochemical analysis of serial 
lung sections of AD (day 7, 14, 21 and 28) and Veh (day 28) treated mice for HO-1 and proSP-C. Arrows 
indicate AECII showing increased HO-1 expression from day 7 of AD treatment. n = 5 mice per group. Scale 
bar = 50 µm. Original magnification: x400. (D) Representative western blot images for HO-1, proSP-C and 
GAPDH (loading control) from 24 hours of AD or Veh treated C57Bl/6 murine AECII’ lysates. n = 3 
independent experiments. (E) Densitometry analysis of triplicate blots of HO-1 and GAPDH and HO-
1*100/GAPDH ratio was calculated and represented as a bar graph. **p < 0.01. (F) Representative western blot 
images for HO-1 and -actin (loading control) from 8, 16 and 24 hours of AD and 24 hours of Veh treated 
MLE12 cells’ lysates. n = 3 independent experiments. (G) Densitometry analysis of triplicate blots of HO-1 and 
-actin and HO-1*100/-actin ratio was calculated and represented as a bar graph. **p < 0.01. (H) 
Representative western blot images for HO-1, COX IV (Mitochondrial marker), LAMP1 (Lysosomal marker) 
and GAPDH (cytoplasmic marker) of the isolated cytoplasmic and mitochondrial-lysosomal (Mito-lyso) 
subcellular fractions from 8 hours of AD or Veh treated MLE12 cells. n = 3 technical replicates. 
 
Similarly, immunoblot analysis of 8, 16 and 24 hours of AD treated MLE12 cells 
demonstrated a significant increase (~ 5 to 2-fold) in HO-1 expression (Figures 4.15F and G), 
with its expression decreasing over time in agreement with its expression pattern in AD 
treated mice lung homogenates. In addition, HO-1 protein significantly increased in the 
mitochondrial-lysosomal fraction obtained from 8 hours of AD treated MLE12 cells (Figure 
4.15H).  
When AD-induced oxidative stress was quenched using the antioxidant, NAC, a prominent 
decrease in the expression of HO-1 protein was noted in MLE12 cells co-treated with AD and 
NAC (2 mM) for 4 hours (Figures 4.16A and B). In line with this, co-treatment of isolated 
murine AECII with AD and NAC (2 mM) for 24 hours also demonstrated a significant 
decrease in the HO-1 protein level (Figures 4.16C and D). Therefore, it is evident that apart 
from initiating mitochondrial biogenesis and mitophagy, AD-induced oxidative stress also 
leads to increased antioxidative response in murine AECII. 
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Figure 4.16. Decrease of AD-induced HO-1 by NAC treatment. 
(A) Representative western blot images for HO-1 and -actin (loading control) from 1 and 4 hours of N-acetyl-
L-Cysteine (NAC) (2 mM) and AD or Veh co-treated MLE12 cells’ lysates. n = 3 independent experiments. (B) 
Densitometry analysis of the triplicate blots of HO-1 and -actin (loading control) and HO-1*100/-actin ratio 
was calculated and represented as a bar graph. **p < 0.01, *p < 0.05, ns - no significance. (C) Representative 
western blot images for HO-1 and GAPDH (loading control) from 24 hours of N-acetyl-L-Cysteine (NAC) (2 
mM) and AD or Veh co-treated C57Bl/6 murine AECIIs’ lysates. n = 3 technical replicates. (D) Densitometry 
analysis of the triplicate blots of HO-1 and GAPDH (loading control) and HO-1*100/GAPDH ratio was 
calculated and represented as a bar graph. **p < 0.01, *p < 0.05. 
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4.4.2. HO-1 independent autophagy in AD treated murine AECII 
Since HO-1 forms a major link between oxidative stress and autophagy and many studies 
demonstrate HO-1 dependent or independent autophagy in different disease conditions, we 
questioned if AD-induced autophagy was HO-1 dependent. In order to address this, siRNA 
mediated HO-1 knockdown (HO1si) versus non-targeting siRNA (NTsi) in MLE12 cells was 
performed for 48 hours, followed by AD or Veh treatment for 8 hours. Knockdown of HO-1 
(Figures 4.17A and B) in AD treated MLE12 cells resulted in a further increase in LC3BII 
protein versus the vehicle (Figures 4.17A and C).  
 
 
 
 
 
 
Figure 4.18. HO-1 independent autophagy in AD treated murine AECII. 
(A) Representative western blot images for HO-1, LC3B and -actin (loading control) from 8 hours of AD or 
Veh treated MLE12 cells transfected with non-targeting siRNA (NTsi) or HO-1 siRNA (HO1si). n = 3 
independent experiments. (B and C) Densitometry analysis of triple target proteins’ blots namely HO-1, LC3B 
and -actin (loading control) and target protein*100/-actin ratio was calculated and represented as bar graphs. 
*p < 0.05, ns - no significance. 
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Figure 4.18. Decreased LC3BII production in AD treated AECII upon chemical inhibition of HO-1. 
(A) Representative western blot images for HO-1, LC3B and -actin (loading control) from 4 hours of SnPP and 
AD or Veh co-treated MLE12 cells. n = 3 independent experiments. (B and C) Densitometry analysis of triple 
target proteins’ blots namely HO-1, LC3B and -actin (loading control) and target protein*100/-actin ratio was 
calculated and represented as bar graphs. **p < 0.01, *p < 0.05, ns - no significance. (D) Representative western 
blot images for HO-1, LC3B and GAPDH (loading control) from 24 hours of SnPP and AD or Veh co-treated 
isolated murine AECII. n = 3 technical replicates. (E and F) Densitometry analysis of triple target proteins’ blots 
namely HO-1, LC3B and GAPDH (loading control) and target protein*100/GAPDH ratio was calculated and 
represented as bar graphs. **p < 0.01, *p < 0.05. 
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In line with this, increased LC3BII levels were observed when primary AECII or MLE12 
cells were co-treated with AD and the chemically inhibitor of HO-1, tin protoporphyrin (25 
µM), a pharmacological inhibitor of HO-1 for 24 hours and 4 hours respectively (Figures 
4.18 A - F). These results thus imply that HO-1 does not induce autophagy in AD treated 
AECII but may serve cytoprotective under AD treatment.  
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Figure 4.19: Proposed model for AD driven aberrant mitophagy and antioxidative response in AECII.  
(1) Upon entry into cells viz AECIIs (by simple diffusion or via organic cation transporters), the cationic drug, AD 
enters mitochondria due to the negative m, where it gets protonated in the acidic intermembrane space and 
dissipates this acquired proton upon reaching the alkaline mitochondrial matrix. Here, the drug inhibits Complex I 
and Complex II of respiratory chain and the -oxidation of lipids, resulting in generation of enormous ROS. (2) 
The increased ROS induces oxidative stress, which further damages the mitochondria, ultimately leading to a 
vicious cycle of production of even more ROS and more oxidative stress, thereby resulting in mitochondrial 
swelling and disruption of m. (3) The oxidative damage inflicted on the mitochondria triggers mitochondrial 
biogenesis and mitophagy. (4) Mitophagy is initiated by fission of the damaged mitochondria from its healthy 
counterpart and primed (most probably) by PINK1/Parkin dependent or independent pathway, resulting in 
increased ubiquitination (ubiquitin.K63) of the outer membrane proteins of the damaged mitochondria. (5) The 
autophagy adapter protein, p62 then recognizes these ubiquitinated mitochondria via its UBA domain and targets 
them into the autophagosomes via its interaction with LC3 on the autophagosomes through the LIR. (6). The 
autophagosomes entrapping the damaged mitochondria are subsequently fused with the swollen lysosomes (since 
the cationic AD is also entrapped by the acidic lysosomes, where AD gets protonated and accumulated, resulting 
in endomembrane pH buffering leading to osmotic swelling and activation of lysosomal biogenesis as a feedback 
mechanism). (7, 8). Inhibition of AD- induced mitophagy or oxidative stress by mdivi-1 and NAC respectively 
reduces the rate of LC3B lipidation. Thus proving, AD steered oxidative stress drives aberrant mitophagy that 
probably leads to enhanced apoptosis of AECII. (9) AD-induced oxidative stress also increases the antioxidative 
response via HO-1, probably resulting from the activation of p62-Keap1-Nrf2 pathway. Further, HO-1does not 
induce autophagy, instead reduces it and serves to be cytoprotective. Text and arrows represented in blue are 
based on the facts derived from pre-existing literature as explained in the penultimate paragraph of section 1.1.5. 
Rest of the figure is depicted based on the findings of this study, except those represented in green text and dotted 
lines, which are mechanism that still remain to be proven in this model. 
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5. Discussion 
The initial focus of the current study was to identify mechanisms underlying AD-induced 
apoptosis of alveolar epithelial cells. As an attempt to study this, siRNA mediated gene 
silencing of Cathepsin D was performed followed by AD treatment in MLE 12 cells. 
However, a significant decrease in cleaved caspase 3, a reliable terminal apoptosis marker, 
was not observed upon Cathepsin D knockdown under AD treatment conditions. It was 
further identified that AD treatment leads to increased lysosomal biogenesis, as indicated by 
increased LAMP1 & LAMP2 both in AD treated mice lungs as well as in AD treated MLE12 
cells in vitro. In addition, AD induces macroautophagy and increased autophagy flux in 
alveolar epithelial cells and inhibition of LC3B, a pivotal protein of macroautophagy 
pathway, attenuates the extent of AD-induced apoptosis of alveolar epithelial cells in vitro.  
Further, in line with the fact that AD is a potential mitochondrial toxicant, a remarkable 
increase in ROS production; particularly a surge in superoxide radicals (O2
.-
) generation has 
been recorded in AD treated mice MLE12 cells and a significant increase in mitochondrial 
biogenesis has also been shown in mice AECII following AD treatment. In continuum, AD 
has been effectively demonstrated to increase the expression of p62 (and not that of BNIP3, 
BNIP3L and NBR1 proteins) in AD treated mice AECII and to promote mitophagy via AD-
induced p62 mediated targeting of dysfunctional mitochondria to autophagosomes and 
lysosomes in AECs. Furthermore, a prominent decrease in LC3B lipidation (LC3BII) has 
been shown upon inhibition of AD driven mitophagy (or) ROS with mdivi-1 and NAC 
respectively in mice AECs and a reduction in annexin V (apoptotic marker) staining has also 
been observed in AD treated AECs following mdivi-1 treatment. In addition, as a 
consequence of AD-induced oxidative stress, a significant increase in the expression of 
antioxidative protein, HO-1 has also been demonstrated in mice AECII upon AD treatment, 
but  knockdown of HO-1 did not reveal a significant decrease in AD-induced autophagy. 
These studies indicate that a) AD-induced extensive apoptosis of AECII is LC3B dependent, 
b) AD steered oxidative stress drives aberrant mitophagy via p62 and c) AD-induced 
autophagy is HO-1 independent. (Figure 4.19). 
 
5.1. Epithelial cell stress and apoptosis in response to AD treatment 
5.1.1. AECII apoptosis in AD-induced pulmonary fibrosis 
AD is a widely used anti-arrhythmic drug that causes fatal pulmonary toxicity, categorizing 
itself under drug induced interstitial lung diseases (ILD). The exact molecular mechanisms 
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underlying AD-induced pulmonary fibrosis remain obscure (Barbas-Filho et al., 2001, Korfei 
et al., 2008, Mahavadi et al., 2010, Wang et al., 2000). But it shares its pathomechnistic 
features with other forms of ILDs like idiopathic pulmonary fibrosis (IPF), where chronic 
injury and apoptosis of AECII, ensuing frustrated alveolar repair are now considered as key 
events (Coward et al., 2010; Günther et al., 2012; Mahavadi et al., 2014; Birkelbach et al., 
2015). Another well characterized observation for ILDs is that injured AECII synthesizes a 
variety of pro-fibrotic enzymes, cytokines and growth factors (E.g. matrix metalloproteinase, 
TGF-, tumour necrosis factor -  (TNF), platelet derived growth factor (PDGF), that lead 
to excessive connective tissue (fibroblast/myofibroblast) deposition, aberrant tissue 
remodelling and subsequent destruction of the lung parenchyma that forms fibrotic lesions 
(Selman et al., 2002), altogether resulting in progressive dyspnea, decline of lung function 
and, ultimately, death (American Thoracic Society/European Respiratory Society 
International Multidisciplinary Consensus Classification of the Idiopathic Interstitial 
Pneumonias.This joint statement of the American Thoracic Society (ATS), and the European 
Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the 
ERS Executive Committee, June 2001, 2002).  In line with this, extensive alveolar epithelial 
cell death and remarkably increased apoptosis of AECII in regions adjacent to the fibroblast 
foci in advanced fibrotic human lung were reported (Myers et al., 1988; Uhal et al., 1998). 
This concept was further supported by appealing observations like severe and pro-apoptotic 
endoplasmic reticulum (ER) stress signaling in AECII from UIP lungs due to familial and 
sporadic IPF (Korfei et al., 2008) and shortened telomere length in the epithelium of sporadic 
IPF subjects (Alder et al., 2008). Other apoptotic changes viz fine and uniformly dispersed 
chromatin within the nuclear membrane and swollen mitochondria with ruptured outer 
membrane have also been documented in the electron microscopic analysis of normal alveoli 
of IPF lungs (Barbas-Filho et al., 2001). The concept of AECII injury as a triggering factor of 
lung fibrosis has also been supported by experimental data in animal models, where anti-
apoptotic agents prevented bleomycin induced lung fibrosis (Wang et al., 2000). AECII 
injury as a result of lysosomal and ER stress leading to apoptosis was also reported in 
Hermansky-Pudlak syndrome (HPS) associated lung fibrosis, a genetic model of lung fibrosis 
(Mahavadi et al., 2010).  
Along the same lines, direct exposure to AD has been demonstrated to induce apoptosis of 
human (Choi et al., 2002, Nicolescu et al., 2007) and other mammalian lung epithelial cells 
(Mahavadi et al., 2014, Bargout et al, 2000). Likewise, induction of TGF-β in lung tissues of 
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AD treated rats (Chung et al., 2001) and apoptosis of AECII in the rat as well as mouse 
model of AD-induced pulmonary fibrosis was also demonstrated (Uhal et al., 2003; 
Mahavadi et al., 2014). Such AECII apoptosis was accompanied by altered surfactant 
homeostasis and epithelial stress (ER and lysosomal stress) in AD treated mice (Mahavadi et 
al., 2014),  again supporting the concept of alveolar epithelial cell injury as a triggering factor 
in the development of lung fibrosis. 
 
5.1.2. Lysosomal alterations in AD-induced pulmonary fibrosis 
Studies from our group have reported increased accumulation of AD-induced multi-lamellar 
bodies (lysosome related organelles) and elevated lysosomal stress indicated by increased 
cathepsin D in mice AECII following AD treatment (Mahavadi et al., 2014). Following this, 
AD driven macroautophagy, a lysosome dependent degradation pathway was also reported in 
mice AECII (Mahavadi et al., 2015). So, in the present study an effort was made to decipher 
whether cathepsin D (or) macroautophagy pathway drives apoptosis in AD treated mice 
AECII. Unlike the HPS associated lung fibrosis, where cathepsin D was demonstrated to 
mediate apoptosis of alveolar epithelial cells (Mahavadi et al., 2010), apoptosis of AD treated 
MLE12 cells was not mediated by cathepsin D.  Instead, knockdown of the major 
macroautophagy protein, LC3B had resulted in drastic down regulation of cleaved caspase 3 
in AD treated MLE12 cells, thus proving a macroautophagy dependent apoptotic pathway 
activation in mice AECII following AD treatment. This corroborates with few earlier findings 
where inhibition of LC3B via LC3siRNA inhibited the activation of caspase-3 and caspase-8 
in cigarette smoke (CS) exposed human bronchial epithelial cells (BEAS-2b) (Kim et al., 
2008b) and LC3B knockout mice demonstrated significant decrease in apoptosis in the lungs 
after CS exposure (Chen et al., 2010). In addition, LC3B knockdown also decreased proSP-C 
in AD treated MLE12 cells, implying macroautophagy dependent dysregulation of proSP-C 
in AECII following AD treatment. These observations therefore point towards a critical role 
of macroautophagy in AD-induced AECII apoptosis, proSP-C dysregulation. 
 
5.1.2.1. Autophagy flux in AD-induced pulmonary fibrosis 
In addition to AD steered lysosomal stress and macroautophagy (Mahavadi et al., 2014; 
Mahavadi et al., 2015), an increase in lysosomal biogenesis was also noticed in mice AECII 
upon AD treatment. This was evident by an increased expression and intense staining of 
LAMP1 and LAMP2 proteins in AD treated mice AECs. This is in line with the facts that AD 
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being a cationic amphiphilic drug gets protonated and accumulated in the acidic milieu of the 
lysosomes, followed by endomembrane pH buffering and inhibition of lysosomal enzymes 
viz phospholipases, which ultimately results in osmotic swelling and feedback activation of 
lysosomal biogenesis (Baritussio et al., 2001, Marceau et al., 2014).  An increase in the 
lysosomal volume have also been reported in other cationic amphiphilic drugs viz imipramine 
(Funk and Krise, 2012) and elevated expression of LAMP proteins have also been 
demonstrated in other lysosomotrophic drugs like chloroquine (Chen et al., 2011).   
Under such proven circumstances of macroautophagy dependent apoptosis and surfactant 
dysfunction and increased lysosomal biogenesis in AD treated AECs, it was imperative to 
determine autophagy flux under AD treatment in order to know if AD induces (or) inhibits 
autophagy. An efficient fusion of autophagosomes and lysosomes was demonstrated in AD 
treated MLE12 cells confirming no blockage in the step of fusion of the autophagic pathway 
(Mahavadi et al., 2015).  So, in an attempt to find if AD induces a late stage autophagy 
inhibition, initial analyses were performed with Baf A1 inhibitor. Surprisingly, the AECs 
treated with AD and Baf A1 revealed loss of vacuolar cytopathology induced by AD. This 
observation was in complete agreement with the report of Morissette et al., 2009, which 
demonstrates that Baf A1, a V-ATPase inhibitor prevents vacuolization and cellular uptake of 
AD. Thus, the notion of measuring autophagy flux for AD using Baf A1 was abandoned. 
Contrastingly, a study by Lee & colleagues reported that AD increases autophagy flux in lung 
epithelial cell lines by using Baf A1 as an autophagy inhibitor to study autophagy flux (Lee et 
al., 2013). Therefore, measurement of autophagy flux in AD treated MLE12 cells were then 
performed using the autophagy inhibitor, chloroquine. Pre-treatment of cells with 
chloroquine, revealed an increase in LC3BII, compared to treatment with AD alone, 
indicating an increase in the autophagy flux in AECs following AD treatment. These 
observations are in full support of previously reported studies, where an induction of 
autophagy and increase in autophagy flux were reported in several other cell types (Lin et al., 
2015; Morrissette et al., 2009). 
 
5.1.3. Oxidative stress and mitophagy in AD-induced pulmonary fibrosis 
5.1.3.1. ROS production in AD-induced pulmonary fibrosis 
AD is a potential mitochondrial toxicant, well known to cause structural and functional 
perturbations to the mitochondria (Bolt et al., 2001, Card et.al., 1998). In fact, AD is 
metabolized by the P450 enzymes system to its metabolite, DEA. Both AD and  DEA have 
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been shown to inhibit -oxidation of fatty acids (Fromenty et al., 1990b, Spaniol et al., 2001) 
and respiratory chain complexes (I and II) and deplete ATP production (Fromenty et al., 
1990a, Bolt et al., 2001, Felsar et al., 2013). In intact hamster lung alveolar macrophages and 
preparations enriched with isolated AECII and non-ciliated bronchiolar epithelial clara cells, 
AD was demonstrated to decrease mitochondrial membrane potential within 2 hours of 
treatment, followed by ATP depletion at 6 hours of AD treatment (Bolt et al., 2001). 
Nicolescu et al., in 2008 reported that this preceding mitochondrial dysfunction has led to 
increased production of ROS in AD treated human peripheral lung epithelial HPL1A cells, 
where it has been demonstrated that incubating HPL1A cells with 100 µM AD for shorter 
incubations ( 2 hours) resulted in a decreased uptake of mitotracker orange, indicative of 
decreased mitochondrial integrity and release of Cyt C, whereas longer incubation times ( 6 
hours) significantly increased ROS formation.  
ROS are grouped amongst key players that modulate the pathogenesis of fibrotic lung 
diseases; including IPF and other forms of interstitial lung diseases viz the drug induced 
pulmonary fibrosis (Kinnula, 2008). ROS involved in various pathologies include radicals 
such as superoxide anion (O2
-), hydroxyl (HO), hydroperoxyl (HOO), lipid peroxyl (LOO), 
carbonate (CO3
-) and non-radical molecules viz hydrogen peroxide (H2O2), singlet oxygen 
(
1
O2), and peroxynitrite anion (ONOO
-
) (Nicolescu et al., 2008). ROS inflicts oxidative 
damage on the mitochondrial lipids, DNA and proteins, which makes mitochondria further 
vulnerable to ROS production (Ashrafi and Schwarz, 2013).  AD has been demonstrated to 
generate 
1
O2 and O2
- photochemically in air-equalibrated aqueous solution (Onoue and 
Tsuda, 2006). In other studies, ESR measurements employing the spin trap, 5,5-Dimethyl-1-
Pyrroline-N-Oxide (DMPO) displayed that AD and a non-iodinated AD analogue (DDIA) 
generates free radicals in simple chemical systems in the presence of oxygen (Taylor et al., 
2003, Nicolescu et al., 2008). In consistence with this, ESR analysis performed in the current 
study with 8 hours of AD treated MLE12 cells employing the spin probe CMH revealed 
increased reactive oxygen species production; particularly a surge in O2
- production was 
evident. Corroborating increased ROS production under AD treatment, markers of oxidative 
stress viz 8-Isoprostane (a product of free radical mediated lipid peroxidation) and oxidized 
protein with carbonyl modifications have been recorded to be elevated in the BALF of IPF 
patients (Kliment et al., 2006, Lenz et al., 1996, Montuschi et al., 1998) and in the exhaled 
breath condensates of interstitial lung disease (ILD) patients (Psathakis et al., 2006, Kliment 
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et al., 2006, Kanoh et al., 2005), indicating ROS driven oxidative stress to be one of the key 
players in the pathogenesis of pulmonary fibrosis.  
Increased ROS also triggers the opening of mitochondrial permeability transition pore 
(mPTP), a trans bi-membrane channel, which allows the passage of solutes up to 1.5 kDa, 
including the release of Ca
2+
, Cyt C, apoptosis inducing factor (AIF) and other pro-apoptotic 
proteins. Opening of mPTP might also lead to the influx of water into the mitochondrial 
matrix resulting in mitochondrial swelling (Hellebrand et al., 2010, Galindo et al., 2003). 
Increased ROS observed under AD treatment were also found to in line with the swollen 
mitochondria observed in the transmission electron micrograph of AECII from AD (day 7) 
treated mice (Unpublished data). AD-induced mitochondrial swelling have also been reported 
in the non-pulmonary cells such as the prostate cancer cell line DU145 (Mitrakas et al., 
2014), lymphocytes (Yasuda et al., 1996), isolated rat liver mitochondria (Kaufmann et al., 
2003) and also in parasitic protozoans viz Leishmania amazonensis and Trypanosoma cruzi 
(De Macedo-Silva et al., 2011, Adesse et al., 2011). Although AD-induced mitochondrial 
swelling has been demonstrated, it should be noted that in certain studies AD has been 
reported as a mitochondrial permeability transition pore inhibitor (Hellebrand et al., 2010, 
Varbiro et al., 2003b). This dual property of AD has been associated with its dosage. At low 
concentrations, AD has been proven to inhibit Ca
2+
 induced mitochondrial swelling and 
prevent the release of pro-apoptotic factors but at higher concentrations, AD has been shown 
to induce cyclosporin A (CsA)- independent mitochondrial swelling (Varbiro et al., 2003a,b). 
The AD metabolite, DEA also induces mitochondrial swelling at higher concentrations 
(Varbiro et al., 2003b). Recently, increased swollen mitochondria with disorganised cristae 
were also described in the IPF lung (Patel et al., 2015) and upon morphometric analyses of 
electron microscopy images, another study group revealed abnormally swollen and 
dysmorphic mitochondria with significantly increased mitochondrial area and frequency of 
large mitochondria exclusively in the AECII of IPF lungs (Bueno et al., 2015). Of note, such 
impairment of mitochondrial function and its contribution towards alveolar epithelial cell 
death was also shown in asbestos induced lung fibrosis (Liu et al., 2013; Cheresh et al., 
2015). 
 
5.1.3.2. Mitochondrial mass in AD-induced pulmonary fibrosis 
Apart from being the toxic by-products of oxidative metabolism, ROS are now considered 
signalling molecules that mediate redox regulation of several processes including 
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mitochondrial biogenesis and mitophagy (Yoboue et al., 2012, Scherz-Shouval et al., 2007). 
Mitochondrial biogenesis and mitophagy are closely coupled events that regulate cellular 
adaptation in response to mitochondrial malfunction, thus playing an active role in 
maintaining mitochondrial and cellular homeostasis. The significance of the intricate 
interplay between these two processes has been emphasized by the aberrantly increased 
mitochondrial content observed in different pathological conditions such as 
neurodegenerative and ageing associated diseases (Palikaras and Tavernarakis, 2014, Kubli 
and Gustafsson, 2012). 
Mitochondrial biogenesis is a sophisticated multi-step process, which involves a highly co-
ordinated transcription and translation of two different genomes (the nucleus and the 
mitochondria) and the recruitment, import and assembly of the resulting newly synthesized 
proteins and lipids into an expanding mitochondrial reticulum (Palikaras and Tavernarakis, 
2014, Yoboue et al., 2012). An increase in mitochondrial mass and mitochondrial DNA 
(mtDNA) content, reflecting an increase in mitochondrial biogenesis has been described in 
H2O2 treated human lung fibroblast cell line (Lee et al., 2000). Similar study in the same cell 
line treated with H2O2 reported an increase in the mRNA levels of nuclear respiratory factor 
1(NRF1), a transcription factor involved in mitochondrial biogenesis (Lee et al., 2002). A 
recent study in a stable cell line expressing a frequently reported human surfactant protein C 
mutation of threonine for isoleucine at codon 73 (hSP-C
I73T
), associated with ILD 
demonstrated an increase in the expression of mitochondrial component, cytochrome c 
oxidase subunit II (COX II), which is suggestive of a rise in the overall mitochondrial 
biomass (Hawkins et al., 2015). Estimation of the mitochondrial content by quantifying the 
ratio of mitochondrial to genomic DNA (mtDNA/gDNA) in the AECII and fibroblasts of IPF 
lungs revealed a significant increase in mtDNA/gDNA ratio exclusively in the AECII of IPF 
lungs but not in the fibroblasts (Bueno et al., 2015). In line with this, AD was shown to 
induce mitochondrial biogenesis in AECs. An increased expression of COX IV, a nuclear-
encoded mitochondrial protein was observed in the AD treated mice lungs, AECII and 
MLE12 cells. In an earlier study employing AD, human hepatoma HepaRG cells were shown 
to induce the expression of peroxisome proliferator-activated receptor gamma co-activator 1-
alpha (PPARGC1A) gene involved in mitochondrial biogenesis (Anthérieu et al., 2011). 
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5.1.3.3. Mitophagy in AD-induced pulmonary fibrosis 
Considering the facts that the ROS regulates Atg4 family of cysteine proteases that are 
important for autophagosome formation (Scherz-Shouval et al., 2007) and that AD mediates 
AECII specific autophagy in murine model of AD-induced pulmonary fibrosis (Mahavadi et 
al., 2015), it was convincing to speculate that AD-induced ROS and mitochondrial 
dysfunction induces mitophagy in mice AECII. Increased co-localization of mitochondrial 
marker protein (COX IV) with autophagosomal (GFP-LC3B) and lysosomal marker proteins 
(LAMP1/cathepsin D) witnessed in AD treated MLE12 cells and AECII directly implies the 
entrapment of damaged mitochondria by autophagic machineries in AECII upon AD 
treatment. In an effort to find the possible pathway that directs such dysfunctional 
mitochondria into autophagic machinery, a methodical analysis of expression of different 
mitophagy proteins were performed in AD treated murine AECII.  
Bnip3L and Bnip3 are the mitochondrial autophagy receptor proteins that directly target 
dysfunctional mitochondria into the autophagosomes via their binding to Atg8 family of 
proteins (Ding and Yin, 2012, Hanna et al., 2012). In the present study, the expression of 
Bnip3L and Bnip3 were found to remain constant in AD treated mice lungs, AECII and 
MLE12 cells. The mitochondrial-lysosomal enriched fractions of AD and Veh treated 
MLE12 cells also exhibited unaltered expression of these proteins. In general, upregulation in 
the expression of these proteins have been reported during their active participations in 
mitophagy (Ding and Yin, 2012; Johansen and Lamark, 2011). Thus, the unaltered expression 
of these proteins rules out the possibility of their involvement in AD driven mitophagy in 
AECII. Concurrent analyses of the expression of autophagy adaptor proteins, p62 and NBR1 
in mice AECII under AD treatment revealed a significant upregulation in the expression of 
p62 in AD treated mice AECII, whereas the expression of NBR1 (except in AD treated lung 
homogenate) remained constant in the AD treated murine AECII. This is in line with the 
previous study from our group that had demonstrated AD-induced transcriptional 
upregulation of p62 in AECs (Mahavadi et al., 2015). In addition, the expressions of 
autophagic proteins ATG12-ATG5 and ATG7, which also play a pivotal role in 
mitochondrial clearance (Wu et al., 2009, Liu et al., 2012) were noted to be prominently 
increased in AECII upon AD treatment. 
Such increase in p62 protein was also reported in both fibroblasts as well as in AECII of IPF 
lungs (Hawkins et al., 2015, Bueno et al., 2015). Although not reported under conditions of 
lung fibrosis, studies from other model systems viz drosophila reveal the recruitment of p62 
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to dysfunctional mitochondria and its crucial role in aggregation via its PB1 domain mediated 
polymerization (in a manner analogous to aggregation of polyubiquitinated proteins) results 
in the clearance of dysfunctional mitochondria (Park et al., 2014, Geisler et al., 2010, 
Narendra et al., 2010). This led us to retrospect the role of increased p62 in AECII under AD 
treatment, specifically with reference to mitophagy. Akin to the aforementioned publications, 
p62 mediated targeting of dysfunctional mitochondria to the autophagic machinery was 
observed in AECs under AD treatment. This is evident from increased co-localization of p62 
with GFP-LC3 and LAMP1/cathepsin D in AD treated MLE12 cells and AECII and also 
from increased p62 detected in the mitochondrial-lysosomal enriched fraction of AD treated 
MLE12 cells. 
Although growing line of evidence strengthens the indispensable role of p62 in mitophagy, 
certain studies (Okatsu et al., 2010, Narendra et al., 2010)identified that p62 is essential only 
for perinuclear mitochondrial clustering but is not required for mitophagy. Okatsu et al., 2010 
reported that upon deletion of p62 in mouse embryonic fibroblasts (MEFs), a gross loss of 
mitochondrial perinuclear clustering was observed without hindering mitochondrial 
degradation. In contrast, Geisler et al., 2010 demonstrated drastic inhibition of mitochondrial 
clearance in p62 knocked down HeLa cells.  A straightforward explanation for these 
contrasting observations is the existence of functionally redundant proteins. For example, the 
loss of p62 could be compensated by the autophagy adaptor protein, NBR1 (Okatsu et al., 
2010, Narendra et al., 2010). This may also explain the unaltered expression of NBR1 in AD 
treated AECII, where abundant p62 could be detected. Interestingly, although total protein 
level of NBR1 remained unaltered, it did co-localize with autophagosomes and lysosomes at 
few perinuclear loci of AD treated MLE12 cells. This may be explained as an outcome of 
polymerization of constantly expressed NBR1 via its PB1 domainunder AD treatment, where 
NBR1 can be part of (or) the chain terminator of a polymeric chain of p62 molecules 
(Johansen and Lamark, 2011).  
Ubiquitination serves as the main denominator for targeting substrates viz protein aggregates, 
mitochondria, peroxisomes, ribosomes and invading bacteria to proteasomal or autophagic 
degradation, thus acting as a ‘Kiss of death’ signal (Kirkin et al., 2009, Shaid et al., 2013). 
The accumulation of p62 in ubiquitin-positive inclusions have been reported in several 
neurodegenerative and chronic liver diseases (Johansen and Lamark, 2011). The anchorage of 
ubiquitin to peroxisomes has been shown to be sufficient for p62 recruitment and pexophagy 
(Kim et al., 2008a). Under AD treatment, an increased expression of ubiquitin.K63 was 
noticed in murine AECII. This is in line with increased accumulation of p62 observed in AD 
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treated AECII, which exhibits a stronger binding towards ubiquitin.K63 chain linkages 
(Kirkin et al., 2009). Further, increased co-localization of ubiquitin.K63 with GFP-LC3B and 
LAMP1 was evident in MLE12 cells under AD treatment. Thus, increased ubiquitin.K63 
drives the recruitment of p62 to the dysfunctional mitochondria, thereby targeting the 
ubiquitinated mitochondria into the autophagic machinery in AECII under AD treatment.  
Parkin, a cytosolic E3 ubiquitin ligase, recruited onto the dysfunctional mitochondria upon 
PINK1 stabilization (Narendra et al., 2008, Narendra et al., 2010) is reported to be 
responsible for ubiquitinating (addition of polyubiquitin chains to lysine-63 or lysine-27) 
various mitochondrial outer membrane proteins viz voltage dependent anion channel (VDAC) 
(Geisler et al., 2010) and induce mitophagy. This is a well established pathway that has 
emerged as a paradigm for mammalian mitophagy (Ashrafi and Schwarz, 2013), where 
mutations in either of genes have been shown to have serious impact on clearance of 
dysfunctional mitochondria (Lee et al., 2010, Park et al., 2006). Recent reports have 
demonstrated the involvement of other E3 ubiquitin ligases such as the Glycoprotein 78 
(Gp78) in inducing mitophagy in a Parkin-independent pathway (Fu et al., 2013). It still 
remains to be elucidated if PINK1/Parkin dependent or independent (involving Gp78 E3 
ubiquitin ligase) ubiquitination of mitochondrial outer membrane proteins occurs in the 
murine model of AD-induced pulmonary fibrosis, amidst recent reports from two 
independent groups revealing quite contrasting observations on the expression of PINK1 
protein in IPF (Bueno et al., 2015; Patel et al., 2015). In addition, another recent study 
reported elevated cytosolic and mitochondrial levels of parkin in a stable cell line expressing 
mutant human surfactant protein C, hSP-C
I73T 
(Hawkins et al., 2015). 
Division (or) fission of mitochondria is a prerequisite for mitophagy (Ding and Yin, 2012, 
Gomes and Scorrano, 2013), therefore inhibition of mitochondrial division should prevent 
mitophagy. Upon treatment of AD treated MLE12 cells with the pharmacological 
mitochondrial fission inhibitor, mdivi-1, a significant reduction in lipidation of LCB, i.e. 
LC3BII and reduction in annexin V staining was observed. This is coherent with decrease of 
cleaved caspase 3 witnessed in AD treated LC3B knocked down MLE12 cells. Thus, the 
inhibition of AD driven aberrant mitophagy displays the potential to prevent AECs apoptosis 
and serves to be cytoprotective. This is in line with many recent studies revealing 
cytoprotection offered by mdivi-1 in several different scenarios such as - protection against 
cell death induced by cigarette smoke in pulmonary epithelial cells in vitro (Mizumura et al., 
2014), attenuation of spinal cord ischemia-reperfusion (IR) injury by reducing neuronal 
apoptosis (Liu et al., 2015), prevention of apoptosis of cardiomyocytes and improving 
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cardiac function induced by renal IR in acute cardiorenal syndrome (Sumida et al., 2015) and 
inhibition of IR injury in primary hippocampal cells by preventing oxygen - glucose deprived 
cell death (Wang et al., 2014).  
NAC is a thiol-containing antioxidant that scavenges several ROS. NAC also acts as a 
cellular source of cysteine for the endogenous production of glutathione (GSH) and 
suppresses the activation of transcription factors viz NF- B (Day, 2008). NAC is used in the 
clinical settings for various purposes especially in context of its antioxidative potential 
(Durukan et al., 2002). Similar to mdivi-1, reduced LC3B lipidation was observed in AD 
treated mice AECII when AD-induced ROS were quenched using the antioxidant NAC. This 
reduced LC3B indicates the probable potential of NAC to prevent AECII apoptosis induced 
by AD steered oxidative stress. This observation with NAC was in coherence with its 
therapeutic potential that had been recently reported to curb AD-induced liver injury in a 
patient (Mudalel et al., 2015) and with the prevention of cytotoxicity demonstrated in AD 
treated mouse fibroblasts (Durukan et al., 2002). Both oral and inhaled NAC treatment have 
been demonstrated to avert drug (E.g. bleomycin (or) AD) induced lung fibrosis in rats, mice 
and hamsters (Day, 2008). In addition, the oral therapy in IPF patients with this FDA 
approved mucolytic drug exhibited an increase in the GSH levels in the ELF of the patients’ 
lungs. Although some improvements have been reported in exercise desaturation and high-
resolution CT images in IPF patients upon NAC inhalation therapy, little to modest changes 
were noted in the pulmonary function tests and quality-of-life scores (Day, 2008). In spite of 
this, the latest INSIGHTS-IPF registry reports treatment of 33.7 % of IPF patients in 
Germany with NAC, ranking second in preference to the treatment with the recently 
approved FDA drug, pirfenidone (44.2 % of the patients) (Behr et al., 2015).  
 
5.1.4. Antioxidative response via HO-1 in AD-induced pulmonary fibrosis 
Since alveolar oxidative stress is resultant of disequilibrium between oxidants and 
antioxidants (Markart et al., 2009) and an increased ROS production has been demonstrated 
in AD treated AECs, an initiative was made to analyze the expression of the antioxidative 
protein, HO-1 under AD treatment. HO-1 is a major inducible antioxidant protein that 
catalyzes the conversion of heme into biliverdin IXα, carbon monoxide and Fe2+ (Donnelly 
and Barnes, 2001). HO-1 is upregulated in response to a variety of stimuli viz free heme, 
oxidative stress, inflammation, heavy metals, UV radiation and so on (Bindu et al., 2011). 
HO-1 also forms a major link to autophagy, and depending on the insult, has been reported to 
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either increase or decrease autophagy in varied pathological conditions  (Yun et al., 2014, Lin 
et al., 2014, Li et al., 2013, Bolisetty et al., 2010, Kim et al., 2008b). In complete agreement 
with the AD-induced ROS, a substantial increase in the expression of the HO-1 was observed 
in AD treated mice AECII. In particular, increase in HO-1 protein was evident in the 
mitochondrial-lysosomal enriched fraction of AD treated MLE12 cells, which implies an 
increased localization of HO-1 to mitochondria in AECs under AD treatment. This is in line 
with studies demonstrating translocation of HO-1 to mitochondria under conditions of 
increased oxidative stress (Bolisetty et al., 2013, Bindu et al., 2011). Further, decreased HO-1 
expression was noted in mice AECII upon co-treatment with AD and NAC, which confirms 
that AD-induced oxidative stress is indeed responsible for the upregulation of HO-1 
expression in mice AECII.   
With an increased HO-1 expression observed in AD treated AECII, it was considered 
important to decipher the role of HO-1 and to address if HO-1 is involved in inducing 
autophagy in AECs upon AD treatment. siRNA mediated knockdown of HO-1 in AECs 
under AD treatment and chemical inhibition of HO-1 using SnPP in AD treated MLE12 cells 
and AECII revealed prominent increase in LC3BII levels. This increase in lipidated LC3B 
upon HO-1 knockdown (or) chemical inhibition of HO-1 indicated a HO-1 independent 
autophagy in AECs under AD treatment. Although AD-induced antioxidative response via 
HO-1 does not seem to completely avert AD driven macroautophagy, its absence did further 
aggravate macroautophagy under AD treatment, which might contribute further towards AD-
induced apoptosis. Thus, the increased expression of HO-1 in AECs upon AD treatment 
might be cytoprotective. 
The nuclear factor erythroid 2 (NF-E2)-related factor 2 - Kelch-like erythroid cell-derived 
protein with CNC homology (ECH)-associated protein 1 (Nrf2 - Keap1) signaling pathway is 
considered as one of the vital cellular defense and survival pathways (Jaramillo and Zhang, 
2013). Nrf2 is a transcription factor, which upon translocation to the nucleus upregulates the 
expression of antioxidant response element (ARE motif) dependent genes like HO-1, in an 
effort to combat cellular insults such as oxidative stress (Ji et al., 2015). In the absence of 
oxidative stress, Nrf2 is associated with the E3-ubiquitin ligase, Keap1 and remains inactive 
in the cytoplasm. Thus, its dissociation from Keap1 activates Nrf2 and facilitates its nuclear 
translocation. The protein p62 is one of the well known players that can execute this job for 
Nrf2. Through its KIR domain, p62 can interact with Keap1 and free Nrf2 (Puissant et al., 
2012). It is thus possible that the increased HO-1 expression witnessed under AD treatment 
might be a result of the activation of p62-Nrf2 antioxidative signaling pathway, since AD has 
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been demonstrated to induce p62 in mice AECII. It is also to be noted that the p62 promoter 
harbours ARE motif, hence the activation of Nrf2 by p62 drives its own transcription, thereby 
contributing to the process of induction of a positive feedback loop (Puissant et al., 2012). In 
line with this, transcriptional upregulation of p62 had been documented in AD treated 
MLE12 cells (Mahavadi et al., 2015). Although compensatory mechanism for oxidative 
stress with upregulated expression of Nrf2 and elevated production of low-molecular weight 
non-enzymatic antioxidants had been demonstrated in IPF patients, they are found to be 
insufficient to counterbalance the oxidative stress (Markart et al., 2009). 
 
Taken together, the current study demonstrates AD-induced macroautophagy to be anti-
survival in AECII and AD-induced oxidative stress to drive aberrant p62-mediated 
mitophagy, that probably drives AECII apoptosis and thereby into development and 
progression of AD-induced pulmonary fibrosis.  
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6. Summary 
Amiodarone (AD) is a bi-iodinated benzofuran derivative, classified as Class III anti-
arrhythmic drug. Despite its therapeutic potential, AD inflicts several cardiac and extra-
cardiac side effects. Being a cationic amphiphilic drug, AD exhibits high lipophilicity. This 
aids in the accumulation of the drug and its metabolite, N-desethylamiodarone (DEA) in high 
lipid containing organs viz adipose tissue, thyroid, liver, lungs and so on, thereby causing 
potentially harmful off-target effects. Although AD mediated thyroid and ophthalmic effects 
are more prevalent, AD-induced pulmonary toxicity (AIPT) is often fatal. Severe pulmonary 
toxicity has been reported in patients receiving even low doses of AD.  Pulmonary fibrosis is 
one of the most frequently reported manifestations of AIPT. Although the precise molecular 
mechanism underlying AIPT still remains obscure, interplay between several direct and 
indirect mechanisms such as cytotoxic insult, immune mediated inflammatory process and 
angiotensin system activation might contribute towards the development of AIPT. Direct 
exposure to AD has been shown to induce apoptosis in various mammalian lung cell types 
including the human alveolar epithelial cells (AECs) in vitro. Apoptosis of alveolar epithelial 
cells (AECII) has been suggested to be a prime factor driving the development of pulmonary 
fibrosis.  
In earlier studies from our group, murine model for AD-induced pulmonary fibrosis had been 
established and a systematic analysis of the same had revealed prominent alterations in the 
surfactant homeostasis, increased endoplasmic reticulum (ER) and lysosomal stress alongside 
with apoptosis of AECII. In line with the increased lysosomal stress, an increase in the 
number and size of lamellar bodies and LC3B lipidation (macroautophagy marker) and LC3 
positive vacuoles were observed in AD treated murine AECII. In continuum, in the current 
study an effort was made to determine the mechanisms underlying AD-induced apoptosis of 
AECII, particularly to decipher the role of macroautophagy, whether it is a pro- or anti-
survival and then determine autophagy flux in AECs under AD treatment. Since AD is also a 
potential mitochondrial toxicant, well known to cause mitochondrial dysfunction and 
generate reactive oxygen species (ROS), further attempt was made to examine if AD 
promotes mitochondrial autophagy (mitophagy) in murine model of AD-induced pulmonary 
fibrosis and thereby discern its probable role. In addition, the antioxidative response via heme 
oxygenase-1 (HO-1) and its role has also been investigated.  
Since AD significantly increases the expression of cathepsin D in AECII and cathepsin D 
mediate apoptosis in AECII in the mouse model of Hermansky-Pudlak syndrome associated 
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lung fibrosis, it was reasonable to speculate the AD-induced AECII apoptosis might be 
mediated by cathepsin D. siRNA mediated gene silencing of cathepsin D in AD treated 
MLE12 cells didn’t result in a significant decrease in cleaved caspase 3, the terminal 
apoptotic marker. As AD was found to induce lysosomal biogenesis (evident from 
prominently increased Lysosomal-associated membrane protein 1 and 2 (LAMP1 and 
LAMP2) expression in AECs under AD treatment) and increase autophagy flux in MLE12 
cells upon treatment with chloroquine, inhibition of the lysosome dependent degradative 
pathway, macroautophagy was hypothesized to attenuate AD-induced AECII apoptosis. 
Knockdown of the major macroautophagy protein, LC3B in AD treated MLE12 cells using 
siRNA resulted in prominent decrease in cleaved caspase 3, indicating the anti-survival role 
of macroautophagy in AECII upon AD treatment.   
Further, being a mitochondrial toxicant, AD was shown to increase ROS production in 
MLE12 cells, particularly a surge in superoxide (O2
.-
) radical generation was observed upon 
AD treatment and a prominent increase in mitochondrial biogenesis, indicated by increased 
COX IV expression was also noted in AD treated AECII.  In addition, AD was demonstrated 
to increase the expression of p62 (and not that of the other mitophagy markers viz BNIP3, 
BNIP3L and cargo receptor protein, NBR1) in AD treated murine AECII. Furthermore, AD 
was shown to promote mitophagy via AD-induced p62 mediated targeting of mitochondria to 
autophagosomes and lysosomes, which is evident from the co-localization of p62, 
ubiquitin.K63 and COX IV with LC3B (autophagosomal marker) and LAMP2/cathepsin D 
(lysosomal marker).  Inhibition of AD-induced mitophagy or ROS in AECs using mdivi-1 
and NAC respectively yielded substantial decrease in LC3B lipidation. In addition, reduction 
in annexinV (apoptotic marker) staining was documented in AD treated MLE12 cells 
following mdivi-1 treatment. As a result of AD-induced oxidative stress, a significant 
increase in the expression of antioxidative protein, HO-1 was recorded in AD treated murine 
AECII and the knockdown analysis using HO-1siRNA in MLE12 cells revealed AD-induced 
autophagy to be HO-1 independent.  
Collectively, the present study demonstrates that a) AD-induced AECII apoptosis is LC3B 
dependent and thus AD-induced macroautophagy is anti-survival in AECII b) AD increases 
oxidative stress and drives aberrant mitophagy via p62 resulting in AECII apoptosis c) AD-
induced  autophagy is HO-1 independent. 
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7. Zusammenfassung 
Amiodaron (AD) ist ein bi-iodiniertes Benzofuran-Derivat welches als Klasse-III 
Antiarrhythmikum klassifiziert ist. Trotz des therapeutischen Potentials weist AD mehrere 
Nebenwirkungen innerhalb und außerhalb des Herz-Kreislaufs auf.Als kationisches 
amphiphiles Molekül ist AD hoch lipophil. Dies führt zur Anreichunerung des Moleküls und 
seines Metabolits, N-Desethylamiodaron (DEA) in Organen mit hohem Lipid-Anteil wie 
unter anderem Adiposem Gewebe, Schilddrüse, Leber und Lunge, welches potentiell 
schädliche Nebenwirkungen verursacht. Obwohl AD-vermittelte Effekte auf Schilddrüse und 
Sehorgane häufiger auftreten, ist AD verursachte Lungen-Toxizität (AIPT) häufig tödlich. 
Selbst in Patienten die nur geringe Mengen von AD zu sich genommen haben, wurde von 
schwerer Lungen-Toxizität berichtet.Lungenfibrose ist eine der am häufigsten gemeldeten 
Symptome von AIPT. Obwohl der genaue molekulare Mechanismus von AIPT noch 
unbekannt ist, kann die Entwicklung von AIPT durch Zusammenspiel von mehreren direkten 
und indirekten Mechanismen wie zytotoxische Schädigung, Immunsystem-basierte 
Entzündungsprozesse und Aktivierung des Angiotensin-Systems unterstützt werden. Es 
wurde gezeigt, dass direkte Exposition von AD in verschiedenen Säugetier-Lungen-Zelltypen 
wie humanen alveolaren Epithelzellen (AECs) in vitro Apoptose auslösen kann. Apoptose der 
alveolaren Epithelzellen (AECII) gilt als einer der wichtigsten Faktoren für die Entwicklung 
der Lungenfibrose.  
In vorrangehenden Studien unserer Forschungsgruppe wurde ein Mausmodell für AD-
induzierte Lungenfibrose etabliert. Systematische Analyse offenbarte prominente 
Veränderungen in der Tensid Homeostase, erhöhter Stress im endoplasmatischen Retikulum 
und in Lysosomen in Verbindung mit Apoptose der AECII. Im Einklang mit dem erhöhten 
lysosomalen Stress wurde auch ein Anstieg in der Anzahl und Größe der Lamellarkörpern 
und LC3B Lipidation (ein Makroautophagie-Marker) und der LC3-positiven Vakuolen in 
AD-behandelten murinen AECII entdeckt. Als Fortführung dieser Arbeit wurde in der 
aktuellen Studie versucht den Mechanismus der AD-induzierten Apoptose in AECII 
aufzudecken. Inbesondere war das Ziel die Rolle der Makroautophagie, entweder als Pro- 
oder Anti-Überlebensfaktor, zu entschlüsseln und den autophagischen Fluss in AECs unter 
AD Behandlung zu bestimmen. Da AD potentiell toxisch für Mitochondrien ist, bekannt 
dafür mitochondriale Funktionsstörungen zu verursachen und reaktive Sauerstoffspezies 
(ROS) zu generieren, wurde weiterhin versucht aufzuklären ob AD mitochondriale 
Autophagie (Mitophagie) im Mausmodell der AD-induzierten Lungenfibrose fördert. 
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Zusätzlich wurde die Rolle der antioxidativen Antwort über Heme Oxygenase-1 (HO-1) 
erforscht.  
Da AD die Expression von Cathepsin D in AECII signifikant erhöht und da Cathepsin D 
Apoptose von AECII im Mausmodell der Hermansky-Pudlak Syndroms assoziierten 
Lungenfibrose vermittelt, lag die Vermutung nahe, dass AD-induzierte AECII Apoptose 
durch Cathepsin D vermittelt wird. Gen-Stilllegung von Cathepsin D durch siRNA in AD 
behandelten MLE12 Zellen führte zu keiner signifikanten Verringerung der Spaltung von 
Caspase 3, dem terminalen Marker der Apoptose. Da entdeckt wurde, dass AD Biogenese der 
Lysosomen induziert (offensichtlich durch erhöhte Expression von Lyosomal-associated 
membrane protein 1 und 2 (LAMP1 und LAMP2) in AECs nach Behandlung mit AD) und 
den autophagischen Fluss in MLE12 Zellen nach Behandlung mit Chloroquine erhöhte, ein 
Inhibitor des Lysosom-abhängigen zersetzenden Signalwegs, wurde angenommen, dass 
Makroautophagie AD-induzierte AECII Apoptose reduziert. Herrunterregulieren des 
wichtigsten Makroautophagie-Proteins, LC3B, in AD-behandelten MLE12 Zellen mittels 
siRNA resultierte in prominenter Verringerung der Spaltung von Caspase 3 und zeigte somit 
die Anti-Überlebensrolle der Makroautophagie in AECII nach AD Behandlung. Weiterhin, da 
AD als toxisch für Mitochondrien bekannt ist, wurde gezeigt, dass AD ROS Produktion in 
MLE12 Zellen erhöht, inbesondere Generierung von Superoxid (O2-) nach Behandlung mit 
AD und eine Erhöhung mitochondrialer Biogenese wurde beobachtet, angezeigt durch 
erhöhte COX IV Expression in AD-behandelten AECII.  
Zusätzlich wurde gezeigt dass AD die Expression von p62 (und nicht die der anderen 
Mitophagie Marker BNIP3, BNIP3L und Cargo Receptor Protein, NBR1) in AD-behandelten 
murinen AECII erhöhte. Weiterhin wurde gezeigt dass AD Mitophagie über AD-induziertes 
p62-vermitteltes Zielen der Mitochondrien zu Autophagosomen und Lysosomen verursacht, 
offensichtlich durch Kolokalisierung von p62, Ubiquitin K63 und COX IV mit LC3B 
(Autophagosomaler Marker) und LAMP2/Cathepsin D (Lysosomaler Marker). Inhibierung 
der AD-induzierten Mitophagie oder ROS in AECs mittels mdivi-1 und NAC führte zu 
substantieller Verringerung der LC3B Lipidation Expression. Zusätzlich wurde Reduktion in 
der AnnexinV-Färbung (Apoptose Marker) in AD-behandelten MLE12 Zellen nach mdivi-1 
Behandlung festgestellt. Als Resultat des AD-induzierten oxidativen Stresses wurde ein 
signifikanter Anstieg der Expression des antioxidativen Proteins, HO-1, in AD-behandelten 
murinen AECII entdeckt und in einer Gen-Stilllegungsanalyse mit HO-1 siRNA gezeigt, dass 
in MLE12 Zellen AD-induzierte Autophagie HO-1 unabhängig ist.  
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Zusammengefasst zeigt die aktuelle Studie, dass a) AD-induzierte AECII Apoptose LC3B-
abhängig ist und damit AD-induzierte Makroautophagie einen Anti-Überlebensfaktor für 
AECII darstellt, b) AD den oxidativen Stress erhöht und anomale Mitophagie mittels p62 
antreibt was in AECII Apoptose resultiert, c) AD-induzierte Autophagie HO-1 unabhängig 
ist. 
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8. Appendix 
8.1. List of primary antibodies 
Name Source Dilution Purpose Company 
Annexin V Rabbit 1:50 IF Abcam 
ATG12-ATG5 Rabbit 1:1000 WB Abcam 
ATG7 Rabbit 1:1000 WB Sigma-Aldrich 
ATG7 Rabbit 1:500 IHC Sigma-Aldrich 
b-actin Rabbit 1:30000 WB Abcam 
BNIP3 Rabbit 1:1000 WB Abcam 
BNIP3L Rabbit 1:1000 WB Cell signalling 
CathepsinD Goat 1:500 WB R&D Systems 
CathepsinD Goat 1:100 IF R&D Systems 
Cleaved caspase 3 Rabbit 1:1000 WB Cell signalling 
COX IV Rabbit 1:1000 WB Cell signalling 
COX IV Rabbit 1:100 IHC Cell signalling 
COX IV Rabbit 1:100 IF Cell signalling 
GAPDH Rabbit 1:1000 WB Abcam 
HO-1 Rabbit 1:500 WB Enzo lifesciences 
HO-1 Rabbit 1:200 IHC Enzo lifesciences 
LAMP1 Rat 1:1000 WB Santa Cruz 
LAMP1 Rat 1:25 IF Santa Cruz 
LAMP2 Rat 1:1000 WB Millipore 
LAMP2 Rat 1:25 IF Millipore 
LC3B Rabbit 1:1000 WB Abcam 
LC3B Rabbit 1:100 IF Abcam 
LC3B Goat 1:25 IF Santa Cruz 
NBR1 Rabbit 1:1000 WB Proteintech 
NBR1 Rabbit 1:100 IF Proteintech 
p62 Rabbit 1:10000 WB Sigma-Aldrich 
p62 Rabbit 1:100 IF Sigma-Aldrich 
p62 Rabbit 1:200 IHC Sigma-Aldrich 
proSp-C Rabbit 1:500 WB Millipore 
proSp-C Rabbit 1:50 IF Millipore 
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proSp-C Rabbit 1:500 IHC Millipore 
Ubiquitin.lysine 63 
specific 
Rabbit 1:25 IF Millipore 
                                   WB:Western blotting, IHC:Immunohistochemistry, IF:Immunofluorescence 
 
 
8.2. List of secondary antibodies 
 
 
 
 
 
 
8.3. List of fluorescent labelled secondary antibodies 
 
 
 
Name Source Dilution Company 
Anti-rabbit Swine 1:2000 Dako 
Anti-goat Rabbit 1:2000 Dako 
Anti-rat Rabbit 1:2000 Dako 
Name Dilution Company 
 
Donkey anti-Rabbit IgG (H+L) Secondary 
Antibody, Alexa Fluor® 488 conjugate  
1:400 Life technologies 
 
Donkey anti-Rabbit IgG (H+L) Secondary 
Antibody, Alexa Fluor® 555 conjugate  
1:400 Life technologies 
 
Donkey anti-Rat IgG (H+L) Secondary Antibody, 
Alexa Fluor® 488 conjugate  
1:400 Life technologies 
 
Donkey anti-Goat IgG (H+L) Secondary Antibody, 
Alexa Fluor® 488 conjugate  
1:400 Life technologies 
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